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CHAPTER I 
 
Background and Research Objectives 
 
HIV-1 and Intrinsic Immunity 
Human immunodeficiency virus or HIV is a retrovirus that infects cells of 
the immune system.  Over time, the immune system becomes weaker; and the 
host becomes more susceptible to infections.  Anti-retroviral drugs have greatly 
lengthened the time a patient advances to the late stages of the disease and 
develop AIDS (acquired immunodeficiency syndrome).  According to the World 
Health Organization 34 million people were living with HIV in 2008, with 2.7 
million people becoming newly infecting.  The devastation and burden on health 
care caused by this virus is clear. 
HIV-1 is the most common strain found in the United States.  HIV-1 
contains nine genes that encode 15 proteins.  In addition to the three major 
proteins common to all retroviruses, Gag, Pol, and Env, HIV encodes four 
accessory proteins, Nef, Vpr, Vpu, and Vif.  These proteins are so named 
because they are dispensable for in vitro replication.  Accessory proteins are 
required for in vivo replication (6).  Two of these accessory proteins, Vif and Vpu, 
have been shown to overcome innate retroviral restriction factors present in 
mammalian cells (80, 97, 103, 140, 151, 152).  Restriction factors can inhibit viral 
replication at various stages of the lifecycle.  It was discovered that these 
accessory proteins counteract proteins important in intrinsic immunity (5, 6). 
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The ability of humans to defend themselves from attacks by 
microorganisms depends mainly on the immune system.  An efficient immune 
response is a very coordinated event.  A successful immune response must clear 
foreign microorganisms while not causing damage to self.  The immune system 
is generally thought of as having two main arms:  the innate and adaptive 
immune responses (139).  The innate response is our body’s first defense 
against microbes and does so in a non-specific manner.  The adaptive response 
is composed of highly specialized cells, B and T cells that recognize only specific 
pathogens.  Following an adaptive response, long-lasting immunity is normally 
developed (157). 
Recently, a form of cell-autonomous immunity has been shown to exist, 
termed intrinsic immunity (14).  Intrinsic immunity combines aspects of both the 
innate and adaptive immune responses.  Intrinsic immunity is provided by 
proteins expressed within cells and serve to protect cells from exogenous viruses 
and endogenous retroelements.  These defense proteins have been termed, 
restriction factors (44, 67).  Several major restriction factors that posses anti-HIV 
activity are; Trim5α, tetherin, Mov10, and some members of the A3 family (50, 
114, 129, 133, 173).  A3G (A3G) is the most studied of the A3 family and the 
most potent restrictor of the family.  All of these proteins have significant effects 
on HIV-1 production. 
Vif is a small 23 kDa protein and one of the four accessory gene products 
of HIV-1.  Viral infectivity factor or Vif is associated with the production of 
infectious viral particles (71).  In vitro experiments determined that while Vif-
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deleted virus can readily infect cells, the progeny virions are 100-1,000 fold less 
infectious than those of wild-type virus (141).  Further experiments determined 
that cells were either Vif-dependent, termed non-permissive, or Vif-independent, 
termed permissive (71).  The great majority of studied cell lines are permissive, 
indicating they support a spreading infection of Vif-deleted virus (107).  Examples 
of permissive cells include 293T, SupT1, and CEM-SS (58).  Primary T cells, the 
major target of HIV in vivo, are non-permissive.  There are a small number of 
non-permissive cell lines, such as HUT78 and CEM T cell lines (134).  These 
results suggested that either permissive cells express a “Vif-like” factor or non-
permissive cells express a restriction factor overcome by Vif.  In 1998, 
experiments using heterokaryons of permissive and non-permissive cells 
determined that the non-permissive phenotype was dominant over permissive 
(92).  Therefore, non-permissive cells likely expressed a restriction factor that 
was overcome by viral Vif.   
 
Discovery of A3G Restriction 
In 2002, using a subtractive-hybridization approach, the restriction factor 
overcome by Vif was identified as apolipoprotein B mRNA-editing enzyme, 
catalytic polypeptide-like 3G or A3G.  A3G (A3G) is a 46 kDa protein (133).  A3G 
is one member of a six-member gene family of DNA-editing enzymes (16).  The 
A3 proteins are clustered on human chromosome 22.  Most of the A3 proteins 
have been shown to posses cytidine deaminase activity (143).  A3G binds RNA 
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and ssDNA (174).  The binding of A3G to ssDNA leads to enzymatic conversion 
of cytidine to uridine. 
A3G binds to the nucleocapsid domain of the HIV-1 polyprotein Pr55 Gag 
(90).  This interaction is essential for A3G incorporation into progeny virions, in 
the absence of Vif.  A3G is released into the target cell following virus entry.  
A3G can then catalyze the cytidine deamination of the negative strand or first 
strand reverse transcripts (17).  These C-to-U changes register as G-to-A 
hypermutations on positive strand DNA.  Interestingly, G-to-A hypermutations 
have been observed in lentiviruses such as HIV-1 and the hepadnavirus, 
hepatitis B virus (111).  These G-to-A hypermutations can either lead to 
degradation of the viral genome or integration of lethally hypermutated provirus.  
Vif interacts with an ubiquitin ligase to form a, Vif-cullin5-elonginB-elonginC 
complex (77).  This complex leads to the degradation of A3G in the producer cell. 
Evidence is accumulating that in addition to the inhibition of exogenous 
retrovirus replication, A3G along with A3F and A3B can inhibit the replication of 
endogenous retrotransposons (40, 165).  It is thus conceivable that the A3 
proteins evolved as a cellular defense to restrict retrotransposition. 
 
A3G-mediated Restriction 
It is believed that A3G and A3F inhibit HIV replication by the same mode 
of action, I will therefore use the term APOBEC to refer to their collective anti-HIV 
activity (60).  Until now, APOBEC activity had only been described to be effective 
in the target cell and not the producer cell.  Packaging of the APOBEC protein 
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into virions is thus essential for anti-viral activity (128).  Virion packaging of the 
APOBEC is facilitated by either binding to viral RNA alone or to both 
nucleocapsid and viral RNA in the producer cell (3).  The APOBEC is released 
into the target cell following virus entry.  The APOBEC can then catalyze the 
cytidine deamination of the negative strand or first strand reverse transcripts 
(174).  These C-to-U changes register as G-to-A hypermutations in the positive 
strand DNA.  A3G causes a specific hypermutation signature in GG dinucleotides 
and A3F activity is distinguished by mutations only in a GA dinucleotide context 
(9, 76).  However, the virus overcomes APOBECs anti-viral activity via Vif.  Anti-
HIV-1 restriction by A3G is shown schematically in Fig. 1-1 (36). 
Of note, G-to-A hypermutations have been observed in the genomes of 
lentiviruses such as HIV-1, including predominance of hypermutation in a GG 
dinucleotide context (an A3G-specific signature) in proviruses from some 
subjects, while others show GA dinucleotide context predominance (an A3F- 
 5
 Figure 1-1.  Restriction of HIV-1 by A3G.  Restriction of HIV-1 and HIV-1 ∆vif by A3G is shown in 
nonpermissive cells.  A3G virion packaging results in inhibition of reverse transcription and 
integration. 
 
Borrowed from:  Cullen, B.R.  (2006) Role and Mechanism of Action of the A3 Family of 
Antiretroviral Resistance Factors.  Journal of Virology, 80( )88 : 1067–1076.
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specific signature) (9).  A gradient of hypermutation in HIV genomes parallels the 
duration that negative strand HIV DNA remains single stranded (122, 142).  The 
hepadnavirus, hepatitis B virus, also contains G-to-A hypermutations and A3G 
also restricts the replication of hepatitis B virus (149).  It is now clear that 
APOBECs are responsible for the high amount of G-to-A mutations found in 
these viruses. 
 
A3G Enzymatic Activity 
Chelico et al., in 2006 and Nowarski et al., in 2008 published opposing 
ideas of how A3G works as an enzyme (28, 106).  Chelico and colleagues 
showed that A3G is a processive 3’-to-5’ cytidine deaminase.  Processive 
enzymes slide along their target substrate, but also can exhibit molecular 
jumping, on the same strand of DNA (28).  Biochemical analysis suggests A3G 
cytidine deamination is accomplished by an A3G dimer.  This would allow for 
easy jumping, since a monomer could disassociate with the ssDNA and re-
associate to the twisted DNA at another point and allow the second monomer to 
“jump” without losing contact with the ssDNA.  A3G is able to jump and slide on 
ssDNA to find cytidines to target for deamination.  The binding of A3G to ssDNA 
is thought to be random.  Several studies have shown that G-to-A hypermutation 
is observed more frequently in the 5’ region of minus-strand cDNA.  This results 
in a 5’-to-3’ gradient of hypermutation.   
 Nowarski et al., showed the exact opposite mode of action of A3G, that 
A3G works by intersegmental transfer (106).  This group showed rather than 
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being processing, A3G works distributively on adjacent cytidines.  In 
intersegmental transfer A3G would make use of both the N-terminal and C-
terminal DNA-binding domains.  This would ensure that contact with the folded 
DNA molecule was not lost, but allow A3G to simultaneously bind two distinct 
regions of the DNA (106).  This would cause dispersed deamination.  Work still 
remains to determine exactly which method of enzymatic activity is employed by 
A3G. 
 The deamination reaction simply is cytidine + H2O = uridine + NH3 (51).  In 
the case of A3G, the zinc finger motif is critical for the coordination of Zn (113, 
166).  The active site of the enzyme is hydrated by water and catalyzes the 
conversion of cytidine to uridine.  The Landau group back in 2004 established 
that A3G enzymatic activity is only targeted against ssDNA (174).  A3G was 
found to not deaminate target sites in ssRNA, dsRNA, or ds DNA. 
 There have been conflicting reports of the necessity of cytidine deaminase 
activity for target cell restriction.  Several studies point to the fact that active site 
mutation of A3G still shows almost normal levels of HIV-1 and HTLV-1 restriction 
(15, 104) . 
 
A3G and Vif Interaction 
It is believed that the region necessary for A3G interaction are mainly in 
the N-terminal region of Vif (123).  Two groups confirm that residues 40-71 
contribute to Vif’s ability to bind A3G.  This binding site however is believed to be 
non-linear.  In that, not all residues in this region when mutated abolish Vif-A3G 
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interaction.  Though the residues involved in A3G binding may not be linear, they 
may represent nearby surfaces in the tertiary structure.    
The Pathak lab in 2007 showed that residues Y40RHHY44 and D14RMR17 
are important for functional interaction and degradation of A3G (123).  Yamashita 
et al., in 2008, identified several residues in the N-terminal half of Vif necessary 
for A3G binding (170).  These mutants W21A, S32A, W38A, Y40A, and H43A all 
poorly bound A3G.  These results extended the binding site identified previously.   
Work from Donahue et al., involving our lab showed that the PPLP motif in HIV-1 
Vif is essential for binding and degradation of A3G (41).  The PPLP motif 
consists of residues 69-72.  It was known prior that this region was critical for Vif-
Vif interaction.  Also, that the PPLP motif was critical for Vif function and 
mutations in this motif lead to decreased virus infectivity.  These results suggest 
that Vif may require homo-multimerization prior to A3G binding.  Indeed, Miller et 
al., in 2007 showed that peptides that block Vif-Vif interaction resulting in the 
production of virions with dramatically increased levels of A3G (99).  They 
proposed that this peptide may provide an effective means of blocking the viral 
counterstrike against our innate cellular defense against HIV-1. 
 The binding sites in A3G necessary for Vif binding have been discovered 
using molecular genetics approaches.  Two studies identified a large region of 
A3G necessary for Vif binding.  Conticello et al., in 2003 identified the region as 
containing residues 54-124 (35).  This was modified by Zhang et al., in 2008 
showing the binding site to lie between residues 105 and 156 (179).  In 2007, 
Huthoff et al., used alanine scanning to show that residues at positions 128-130 
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to be most critical (64).  D128 had already been known to play a role in the 
species specificity of the A3G-Vif interaction.  Additionally, they found that the 
proline at position 129 and the aspartic acid at 130 contributed to an overall 
negative charge that was necessary for Vif binding. These residues are very near 
residues Y124 and W127 which are known to be vital for A3G packaging.  Any 
pharmacologic agents that target the A3G/Vif interaction would have to do so 
without preventing the ability of residues 124 and 127 to aid in virion packaging.   
 In 2009, the Pathak lab extended the A3G binding site, demonstrating that 
amino acids 126-132 were important for Vif binding (124).  However, they found 
that the A3F binding site for Vif was located between amino acids 283 and 300.  
This shows two related proteins with very distinct regions necessary for Vif 
interaction.  Indeed, the A3G and A3F binding site interact with different regions 
of Vif. 
 
Vif-mediated A3G degradation 
The mechanism of Vif-induced A3 degradation is well-understood.  Vif 
recruits (Ub)-activating (E1), Ub-conjugating (E2), and Ub-ligating (E3) enzymes 
(77).  The most diverse of these complexes are the E3 Ubiquitin ligase enzymes.  
Vif recruits an E3 complexes containing Cullin 5 as a core component.  Elongin C 
also binds and recruits the E3-ubiquitin ligase complex poly-ubiquinates A3G 
leading to A3G’s proteasomal degradation.  Vif contains a SLQ(Y/F) motif similar 
to those found in SOCS proteins (13, 96, 97).  This consensus sequence in 
SOCS proteins link proteins for degradation with a multisubunit E3 ubiquitin 
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ligase.  Vif then forms the Vif-cullin5-elonginB-elonginC complex.  This complex 
interacts with A3G and A3F and lead to proteasomal degradation in the producer 
cell.  Intriguingly, A3B also inhibits HIV-1 replication, but in a Vif-independent 
manner (40).  However, A3B expression is restricted and may not normally be 
expressed in lymphocytes. 
The N-terminal region of Vif contains a zinc coordination site, HCCH 
(between residues 100-142), which binds to cullin 5 in the absence of elongin C 
(98, 113).  Mutations in this region impair zinc coordination, cullin 5 binding, and 
thus inhibit A3G degradation.  Vif is monoubiquitinated in the absence of A3G, 
this has no impact on its half-life (97).  However, when coexpressed with A3G, 
Vif becomes polyubiquitinated and is degraded.  This indicates that Vif protein is 
also degraded during the process of A3G degradation and so the virus must 
continually express Vif to pose an effective anti-HIV response.  The PPLP motif 
in Vif has also been shown to be necessary for both A3G binding and 
degradation (41). 
Iwatani et al., in 2009 showed that four lysine residues in the C-terminal 
half of A3G are the targets of polyubiquitination (65).  These residues, Lys-297, 
301, 303, and 334 when mutated block Vif-mediated degradation.  When all four 
lysine residues were mutated to arginine A3G was completely resistant to Vif and 
able to restrict reverse transcription in the target cell. 
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Low Molecular Mass and High Molecular Mass A3G 
A3G exists in two major forms in cells, low molecular mass (LMM) and 
high molecular mass (HMM) (31, 32).  The LMM form is enzymatically active in 
deaminating cytidines. The size of LMM form ranges from 46 kDa to about 160 
kDa in size.  The LMM is likely composed of A3G monomers, dimers, trimers, 
and tetramers. The HMM form is inactive for cytidine deaminase activity.  The 
HMM complex can range in size from 700 kDa to 2 MDa.  HMM A3G is found in 
activated T cells and naïve T cells in tissues, both of which allow incoming Vif-
positive HIV genomes to be reverse transcribed and integrated (31).  
Furthermore, the presence of Vif contributes to production of infectious virions 
from activated T cells.  Both Vif and polyubiquinated forms of A3G were identified 
as cofractionating with HMM A3G complexes (31).   
In 2005, experiments demonstrated that endogenous LMM A3G can 
restrict incoming virus at the reverse transcription stage (31). Chiu and 
colleagues in the lab of Warner Greene showed resting T cells possessed mainly 
LMM A3G, while activated cells had HMM A3G.  Following T cell activation, LMM 
A3G was shown to shift into the HMM complex by high performance liquid 
chromatography.  It was initially thought these experiments answered long-
standing questions about why resting and naïve T cells in the blood possess a 
post-entry block to incoming HIV genome replication.  siRNA-mediated 
knockdown of LMM A3G in resting T cells effectively relieved the early replication 
block during reverse transcription in these cells and allowed for the production of 
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significant amounts of virus.  However, since the initial report these experiments 
have not been replicated. 
Chen and colleagues repeated the experiments by Chiu using the same 
siRNA and others, one of which showed 2 fold more reduction in A3G levels 
compared to the initial Chiu construct (70).  They were unable to discern an 
effect on the infectivity of resting T cells after A3G knockdown.  Additionally, 
Santoni conducted experiments in which T cells were activated by PHA and IL-2 
and transduced with various vectors that expressed Vif, siRNA directed against 
A3G, or control scrambled siRNAs (127).  The cells were then maintained in low 
IL-2 and allowed to return to a resting phenotype.  The post-activation cells were 
then infected with a fluorescent reporter HIV-1.  They found that although A3G 
expression was reduced by Vif and or siRNA directed against A3G, there was no 
correlation between HIV resistance and the amount of A3G present in the 
cytoplasm. 
These HMM complexes were thought to be aggregated protein in the 
cytoplasm with no function due to their lack of enzymatic activity.  But, Wichroski 
et al., in 2006 showed that HMM or A3G complexes colocalized with γ-tubulin, 
but not vimentin (164).  Vimentin is known to form cages around aggresomes.  
They also showed these bodies to be distinct from those cytoplasmic bodies 
formed by another HIV-1 restriction factor, Trim5α.  Multimerization of A3G was 
found to be RNA-dependent by Opi et al., in 2006 (110).  
I call the HMM form, A3G complexes.  A3G complexes are the focus of 
the work presented here.  Until now, there was no known role for these 
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complexes in HIV-1 replication.  I show that A3G complexes decrease HIV-1 
production, likely by reducing the half-life of HIV-1 Gag. 
 
A3G and RNA Granules 
The HMM complex contains on average 100 different proteins (32, 78, 
159).  These proteins represent many classes from chaperones (Hsp70, Hsc70, 
Hsp 60), hnRNA (Nucleolin, Ro, and La), dead box proteins (DDX1, DDX5, 
DDX3), ribosomal (40S S11, 60S S15a, 60S P2, L28, and S6), transcriptional 
regulators (NFAR),  translational regulators (CBP80, PABPC1, eIF4e-G1, Dcp1), 
molecular motors (kinesin heavy chain, β -tubulin), and RNA processing proteins 
(staufen, Pur β, TAP RNA transporter, GW182).  Rana first showed that these 
HMM complexes colocalized with structures known as RNA granules using 
confocal microscopy.  Co-immunoprecipitation experiments showed that most of 
these proteins interaction with A3G were RNA dependent (164). 
RNA granules are non-membrane bound structures that are used for RNA 
storage and degradation or for localized translation (7).  RNA granules are highly 
dynamic in nature.  Proteins normally come together to perform a specific 
function related to RNA metabolism or storage and then disassemble.  There are 
several classes of RNA granules; germ cell granules, neuronal (Staufen) 
granules, stress granules, and processing bodies (7). 
Germ cell granules are so named because they are found in germ cells 
and function during development (52).  These Ribonuceloprotein particles 
contain maternal mRNA required for germ cell specification.  These granules 
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store RNA until various stages of development are reaches and disassemble to 
allow the translation of the maternal mRNA at the correct time. 
Neuronal granules are also termed Staufen granules.  These granules 
contain translational machinery and allow for localized translation at distant 
synaptic structures (75).  In neurons that can be considerable in size, it would 
take a long time for information gathered at far synapses to reach the nucleus to 
initiate translation and then translation.  Therefore, neurons store critical 
mRNA’s, such as those for neurotransmitters, in granules in synapses so that 
incoming information can quickly cause the localized translation of important 
proteins. 
Stress granules are induced during periods of cellular stress (78, 162).  It 
is believed that during stress certain housekeeping mRNAs are shuttled into s 
tress granules to delay their translation in favor of proteins needed for cellular 
survival.  These include heat shock proteins, such as molecular chaperones.  
This increases the rate of synthesis of critical proteins. 
Processing bodies (P-bodies) are sites of both mRNA storage and decay 
(22, 52).  RNAs can be shuttled into P-bodies for storage, so that they can be 
later translated at the appropriate time.  RNAs in P-bodies can also be destined 
for degradation, by P-body/late endosome interactions.  P-bodies contain many 
of the mRNA decay factors.  It was once believed that P-bodies also contained 
the RISC complex and were necessary for miRNA- and siRNA-mediated gene 
silencing.  Teixeira et al., in 2005 showed that P-Bodies are sensitive to RNase, 
reminiscent of the early studies of HMM complexes (146).   
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However, evidence is accumulating that suggests that a separate 
structure termed GW-bodies are responsible for miRNA-induced gene silencing 
(55, 88, 120).  These GW-bodies are so named do to their abundance of GW182, 
while most P-bodies have little to no GW182.  GW-bodies have been shown to 
interact with late endosomes and Multi-vesicular Bodies or MVB’s. 
The cellular function of A3G may be closely related to RNA granules and it 
is important to note that others have found that A3G may shuttle between 
polysomes and stress granules (22).  Polysomes are strings of ribosomes joined 
by a common mRNA.  They function to synthesize several polypeptides 
simultaneously from a common mRNA, as such polysomes are variable in length.  
These researchers found A3G bound to RNA at polysomes, specifically HIV-1 
RNA, and these A3G-mRNA complexes moved from polysomes to stress 
granules, under experimentally induced stress.  Stress granules and P-bodies 
contain a protein named, Mov10 (24, 50). 
 
Newly Discovered HIV-1 Restriction Factors 
Mov10 is a component of RNA granules that restricts HIV-1 replication at 
multiple-stages of the replication cycle (24, 50).  Mov10 is a putative RNA-
helicase and part of the DExD superfamily of proteins.  The overexpression of 
Mov10 in the producer cell leads to the reduction of HIV-1 Gag (24).  Mov10 is 
also packaged into the virion and reduced viral infectivity.  The reduction in Gag 
levels leads to reduced virus output. 
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A3G and Mov10 colocalize in cells.  Overexpression of A3G and Mov10 
led to significant reductions in the proteolytic cleavage of HIV-1 Gag (24).  This 
inhibition was additive, in that A3G and Mov10 expression alone decreased Gag 
cleavage.  Overexpression however, has no effect on the infectivity of the 
resulting virions.  The mechanism for this inhibition is yet to be established. 
MicroRNA’s or miRNAs are about 22 nucleotides in length and work in 
conjunction with the RNA-induced silencing complexes (RISC) to downregulate 
gene expression.  The RISC complex is also known to localize to P-bodies.  The 
exact role of P-bodies in miRNA-mediated gene expression is unclear.  Studies 
have found them to be both necessary and unnecessary for miRNA gene 
regulation.  miR29a has been shown by two groups to restrict HIV-1 production 
(102). 
miR29a is expressed highly in activated T cells.  Rana and colleagues 
found that disruption of P-bodies lead to increased levels of HIV-1 production 
(102).  They showed that miR29a was able to bind to the 3’UTR of HIV-1 RNA 
and transport the RNA to P-bodies.  miR29a action lead to reduced virus output 
and viral infectivity.  One group also found that miR29a can reduce the 
expression levels of HIV-1 Nef (2).   
I present work in this thesis that knockdown of P-body component 
RCK/p54 leads to increased HIV-1 production.  This increase is the result of at 
least two independent events.  RCK/p54 knockdown abrogates P-body formation 
which allows for HIV-1 RNA that otherwise would be stored in P-bodies to be 
translated.  RCK/p54 knockdown has a second independent effect in cells 
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containing A3G.  A3G complexes are abrogated, which increases HIV-1 Gag 
half-life and allows for higher virus production. 
 
A3G Structure 
 Several groups have studied the C-terminal domain of A3G.  This has 
resulting in at least three NMR structures and now two X-ray crystal structures.  
The two X-ray crystal structures differ, but the latest one supports information 
provided by the NMR structures.  This latest crystal from Shandilya et al., 
structure posses four large interfaces that they hypothesize may play an 
important role in A3G homo-oligomerization (132). 
 A3G contains two consecutive Z motifs.  These Z motifs give the enzyme 
order.  The A3G contains 2 zinc coordination sites or zinc fingers that work by 
way of one histidine and two cysteines (132).  The consensus sequence of 
Hx1Ex24-28PCx2-4C is present across the entire A3 family.  Likewise, like other 
cytidine deaminases A3G posses a core α-β-α fold.  The crystal structure by 
Holden et al., in 2005 showed conservation of the active site with known 
structures of other cytidine deaminases (62). 
The C-terminal domain consists of a five-stranded β sheet that is 
surrounded by six α-helices.  Four large interfaces are present that others 
speculate could be potential oligomerization sites (132).  However, these sites 
are not believed to be present in the N-terminus.  Oligomerization is thought to 
be playing a key role in A3G enzymatic activity.  Also, the HMM complex of A3G 
is a large ribonucleoprotein complex and multiple sites for interaction with itself 
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and with other proteins and RNA would explain the ability of A3G to form these 
large complexes within the cell. 
The N-terminal region of A3G has been modeled by Zhang et al., using 
structures of APOBEC2 (178).  Many mutations that result in the species-
specificity of A3G and the ability of A3G to homo-oligomerize and are required for 
virion-packaging are in this region.  This model predicts that these residues are 
under positive-selection pressure and are on exposed surfaces in the protein, 
which would confirm their importance.  Specifically, D128K is present in an 
exposed α helix, helix 4.  This structural model also suggests a surface hot-spot 
domain that includes residues R122-W127.  These amino acids have been 
shown by several groups to be important in the packaging of A3G into virions.  
Also, mutation in this region seems to affect A3G ability to interact with the 
nucleocapsid region of HIV-1 Gag and non-specific RNA binding.  Bennett et al., 
in 2008 demonstrated that the C-terminal deaminase domains of A3G are 
necessary for A3G dimerization (12).  Specifically, residues 209-336 were found 
to be necessary and sufficient for homoligomerization.   
I make use of the D128K, Y124A, and W127A mutants in my work 
presented in Chapter II to determine the role of A3G complexes in an anti-HIV 
effect.  These mutations all lie in a region undergoing positive selection and are 
required for anti-viral activity.  The structure of A3G may give clues as to the 
regions of A3G necessary for A3G complex formation. 
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A3F and A3B 
A3G is the most potent of the A3 family in restricting HIV-1 and thus has 
been the most studied.  However, several other A3 proteins have been shown to 
possess anti-viral activity.  A3F and A3B are such A3 family members (40, 86, 
180).  A3F not only restricts HIV-1 replication, but posses decreased sensitivity to 
HIV-1 Vif –mediated degradation (87).  A3B has been shown in the lab to have 
limited ability to restrict HIV-1, but completely resistant to HIV-1 Vif-mediated 
degradation.  In patients, the G-to-A hypermutation preference is mostly of the 
A3G mutation signature.  However, the A3F mutation signature is rather 
prevalent.  A3G deaminates cytosines that are preceded by another cytosine, 5’-
CC.  A3F preference is for a cytosine that is preceded by a thymidine, 5’-CT.   
A3G and A3F are expressed in the peripheral blood lymphocytes, the 
spleen, ovary, and testes; A3B has not been found in these tissues.  A3B has 
been found expressed in various cancel cell lines (20, 121).  As such, most effort 
has been focused on A3G and A3F being that they are expressed in 
lymphocytes.  A3B is not expressed in any of the natural cellular targets of HIV-1 
and likely plays no role in restrictive HIV-1 in vivo. 
Like A3G, A3F forms HMM complexes (164).  A3F can homo-oligomerize 
and it is believed it can hetero-oligomerize with A3G too.  A3F mRNA has been 
found within HMM complexes.  The APOBEC family of proteins is shown in Fig. 
1-2 (66). 
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Figure 1-2.  The human APOBEC family of proteins. A3B, A3G, A3F, and A3D posses anti-HIV 
activity.  A3B, A3G, A3F, and A3C all restrict the replication of at least one endogenous 
retroelement. 
 
Borrowed from:  Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., and 
Navaratnam, N.  (2002)  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on 
chromosome 22.  Genomics, 79 (88), 285-96. 
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A3G Virion Packaging 
 Approximately 4 to 11 A3G molecules are packed into each virion (115).  
One molecule of A3G per virion may not be enough for virus neutralization.  
Paradoxically, it may even improve viral fitness by producing drug resistant 
mutations, or even mutations that help the virus to invade the immune system. 
Though conflicted reports were initially reported in the literature about the 
necessity of RNA for A3G packaging, it is thought that A3G packaging requires 
interactions with HIV-1 Gag nucelocapsid and non-specific interactions with RNA 
(90).  Warner Greene’s lab showed using pulse-chase experiments that newly 
synthesized A3G is packaged into budding virions (138). Though their data 
showed that HMM complexes form within the same time as needed for virion 
incorporation, they simplest explanation of the data was that LMM A3G was 
packaged into the virion.   
The RNA necessary for A3G packaging is not entirely clear.  It is known 
that NC is responsible for binding of HIV-1 genomic RNA, but a small RNA, 7SL 
has also emerged as being critical for A3G packaging (10, 158).  Burnett et al., 
showed that multimers of A3G were recruited to the plasma membrane, the site 
of virus assembly (25).  This lent further evidence for the necessity for A3G-A3G 
interactions in A3G function.  Using FRET, these multimers of A3G were shown 
to colocalize with Gag during viral assembly.   
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Immunology of A3G 
Multiple studies have shown a great variation of A3G and A3F expression 
from patient to patient.  This led researchers to examine if differences in A3 
expression could lead to differences in disease progression.  There has been 
some disagreement in the literature on this subject.  Jin et al., showed an inverse 
relationship between A3G mRNA levels and viral load in HIV infected patients not 
on therapy (69).  A positive relationship was observed between A3G mRNA level 
and CD4 count.  These results were highly statistically significant.  In fact, they 
found that long-term nonprogressors (infected individuals who show no signs of 
HIV-1 disease progression, without anti-retroviral therapy) had the most A3G in 
PBMC’s, while uninfected subjects had an intermediate level, and progressors 
had the least amount of A3G.   In 2009, Vazquez et al., made very similar 
findings when examining A3G levels in uninfected HIV-1 exposed individuals. 
Upon exposure, these individuals expressed high levels of A3G (154).  After 
removal of the exposure A3G levels decreased.  This work suggested that HIV-1 
may trigger A3G expression. 
In 2006, Cho et al., found a positive correlation in HIV-1 infected 
individuals between A3G and A3F mRNA levels and viral load (33).  Specifically, 
infected patients had lower levels of A3G and A3F expression.  There was no 
correlation found between A3G and A3F mRNA levels and CD4 count.  In 2010, 
Reddy found no correlation between A3G expression and either viral load or CD4 
T cell count (117).  Ulenga et al., in 2008 examining hypermutation  in various 
regions of the virus found that higher levels of hypermutation did not correlate 
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with decreased viral load, suggesting that hypermutation is not the major 
mechanisms by which A3G restricts HIV-1 replication (150).  Work still remains to 
determine the effect of A3 expression levels on disease progression. 
Work from our lab led by Michael Vetter in 2009 showed variation in the 
amount of A3G expressed in various CD4 T helper lymphocyte subtypes (156).  
This difference led to differences in HIV-1 infectivity.  Specifically, Th1cells 
contained higher levels of A3G and A3F RNA and protein, while Th2 cells had 
significantly less A3G and A3F expression.  T cell activation increases A3G 
expression and this was seen in Th1 cells, but not in Th2 cells that already had 
low levels of A3G.  Th1 cells produced viruses with more A3G and thus greatly 
reduced infectivity in contrast to Th2 cells, which produced virions with 
significantly higher infectivity.  This showed that A3 expression changes with 
CD4 T cells differentiation and could account for higher infections in one subtype 
over another. 
 
Research Objectives 
 The main objectives of this research project were (1) to determine if A3G 
complexes are necessary for A3G packaging into progeny virions (2) to 
determine if A3G complexes play a role in restricting HIV-1 in producer cells and 
(88) to examine the interaction between RNA granules with A3G complexes.  
Chapters II and III of this dissertation contains work that answers questions 1 and 
2.  In Chapter I, I showed that A3G complexes decrease HIV-1 production.  In 
Chapter III I extend this knowledge and also showed that RCK/p54 knockdown 
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abrogates A3G complexes and this A3G-mediated restriction on HIV-1 
production.  This work was aided by use of a previously described mutant of A3G 
(C97A).  Using this mutant, I show that A3G complexes are dispensable for A3G 
packaging into progeny virions.  Further, I show that A3G complexes do play a 
role in an anti-HIV-1 response.  I demonstrate that the presence of A3G 
complexes limits the production of HIV-1 from producer cells.  My working model 
suggests that HIV-1 Gag is trapped in A3G complexes; away from the site of viral 
assembly.  The Gag in A3G complexes is then targeted for degradation, resulting 
in decreased HIV-1 production.  In Chapter III I examine the interplay between 
RNA granules and A3G complexes.  I show that A3G likely resides in a granule 
that is only formed when A3G is present.  This granule contains the processing 
body markers RCK/p54 and Dcp1, but little to no GW182.  Most importantly, 
these A3G complexes are disrupted by siRNA against RCK/p54 and this 
disruption releases the A3G-mediated restriction on virus production, extending 
findings from Chapter II that A3G complexes restrict HIV-1 production. 
 Taken together, this work provides one of the first in-depth studies of A3G 
complexes.  These structures were thought before to be inert, a belief likely held 
due to their absence of enzymatic activity.  But, I show that A3G complexes are 
active against HIV-1 in the producer cell.  Previously, A3G was thought to only 
act against HIV-1 in the target cell.  This represents a novel anti-HIV restriction of 
A3G and could lead to the development of therapies that disrupt the Vif/A3G 
interaction and augment the transit of HIV-1 Gag to A3G complexes.  It is 
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possible that this restriction is not only HIV-1 specific, but may affect other 
viruses restricted by A3G, such as Hepatitis B virus. 
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CHAPTER II 
 
A3G Decreases Human Immunodeficiency Virus (HIV-1) Production 
 
Introduction 
Members of the A3 family of cytidine deaminases (A3B, A3D/E, A3F, A3G, 
and some variants of A3H) can restrict human immunodeficiency virus type 1 
(HIV-1) replication in human lymphocytes (19, 30, 37, 86, 119, 180).  The most 
studied and potent of these anti-viral enzymes is A3G (A3G) (91).  HIV has a 
counter-measure to this host-defense, the virion infectivity factor (Vif) (105).  Vif 
recruits a cullin-RING ubiquitin-ligase complex that marks A3G for proteasomal 
degradation, thereby precluding its packaging into virions (97, 175).  In the 
absence of functional HIV-1 Vif, A3G is packaged into progeny virions via RNA-
dependent interactions with the nucleocapsid (NC) domain of HIV Pr55 Gag to 
confer antiviral effects in the target cell (74, 177). Although some reports support 
the assumption that viral countermeasures, such as Vif, limit A3s’ antiviral effects 
to only blocking vif-defective HIV-1 or retroviruses from other species, several in 
vitro and in vivo studies of HIV-1 indicate that there are some antiviral effects of 
A3G in vif-positive HIV-1 virions and HIV-1 target cells (68, 112, 155, 156). 
Similarly, murine A3 has been demonstrated to have activity in vivo against 
several exogenous mouse retroviruses (1, 59, 89, 108).  Therefore, human A3’s 
likely have physiological relevance for human retrovirus infections in vivo. 
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Previous studies of A3G’s subcellular localization observed both diffuse 
cytoplasmic staining and localization to large, punctate cytoplasmic foci.  Reports 
suggest that the cytoplasmic bodies may be RNA granules such as mRNA 
processing bodies (P-bodies), Staufen granules, or stress granules (54, 78, 163).  
High performance liquid chromatography (HPLC) has characterized the diffuse T 
cell A3G as being in a low molecular mass (LMM) form and the aggregated form 
in high molecular mass (HMM) complexes (32). An alternate method involving 
ultracentrifugation has also been validated to differentiate these two forms (116).  
The large HMM complexes have been identified as including A3G multimers, 
several pol III-transcribed RNAs, and a large number of other associated 
proteins, many found in more than one of the RNA granules listed above (32, 53, 
54, 78).  HMM complexes of A3G have also been implicated in restricting 
endogenous retrotransposons such as Alu (32, 63).    
I examined the functional effects of cytoplasmic complexes of A3G on 
HIV-1 replication in HIV-1 producer cells. I called the cytoplasmic structures ‘A3G 
complexes’ here, because the earlier data implicated A3G co-localization with 
different RNA granules, the current models of these structures posit that some 
constituents dynamically exchange among different RNA granules, and my data 
also suggested dynamism of A3G (8, 73, 81, 147, 160, 176).  A C97A A3G 
mutant was confirmed to have delayed A3G complex formation and then used in 
a comparison to wild-type A3G (109, 110). HIV-1 particle release was enhanced 
from cells lacking A3G complexes and having abundant LMM A3G. A p6-deleted 
HIV-1 Gag that is retained intracellularly decayed more slowly after protein 
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synthesis inhibition from cells lacking A3G complexes.  Comparison of Vif-
positive and Vif-negative HIV-1 strains which either did or did not deplete 
endogenous A3G complexes from producer T-cell lines, respectively, confirmed 
that this decrease in HIV-1 production is not an artifact of over-expression. I 
conclude that A3G complexes reduce HIV-1 production likely via a mechanism 
that increases Gag degradation.  This work will lead to better understanding of 
the regulation and function of A3G complexes. 
 
Materials and Methods 
Cells, transfections, and HIV-1 p24 antigen ELISA   
HeLa cells were maintained in DMEM supplemented with 10% fetal bovine 
serum (FBS, HyClone), penicillin (50 IU/ml), and streptomycin (50 µg/ml). CEM 
and CEM-SS cells were cultured in RPMI 1640 supplemented with 10% FBS, 
penicillin (50 IU/ml), and streptomycin (50 µg/ml).  Transfections were performed 
by transient transfection using polyethylenimine (PEI) (118).  Complete growth 
media was replaced 30 minutes prior to transfection.  Transfections were carried 
out in 6-well plates and the reaction included 2 µg of DNA and 10 µg of PEI 
diluted in 250 µl of serum-free media, unless otherwise stated.  
HIV-1 p24 antigen ELISA was carried out as previously described (156, 
161).  Virus-containing supernatant fluids were collected and filtered through a 
0.45 µm syringe filter, prior to ultracentrifugation through a 20% sucrose cushion 
(detailed below).  Cellular and viral lysates were prepared using ice cold lysis 
buffer [50 mM HEPES, pH 7.4, 125 mM NaCl, 0.2% NP-40 and 0.1 mM PMSF 
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and EDTA-free protease inhibitor cocktail (CalBiochem, San Diego, CA 
#539137)].  The percentage p24 release was calculated as culture supernatant 
ultracentrifugation pellet p24 antigen concentration divided by the total p24 
antigen concentration (cell + culture supernatant ultracentrifuge pellet 
concentration).  Others have previously used this method to determine changes 
in percent p24 antigen release (56, 152).  The HIV-1 p24 antibody 183 detects 
Gag precursors polypeptides Pr55 and 41, as well as processed p24 capsid 
protein (CA), within the cell and processed p24 CA within the virion (151, 152).  
Primary CD4+ T lymphocytes were isolated from an uninfected donor 
using a protocol approved by the Vanderbilt IRB.  CD4+ T lymphocyte isolation 
was via a negative-selection (Stem Cell). Anti-CD3/CD28 beads (Dynal) were 
used for T cell activation at a ratio of 1:1 for 3 days.  2 million CD4+ T 
lymphocytes were washed in cold PBS and lysed in 60 µl of ice cold lysis buffer 
(60 mM NaCl, 50 mM HEPES pH7.4, 0.2% NP-40, 0.1 mM PMSF and 1xEDTA-
free protein inhibitor cocktail) by vortexing.  Following 10 minute incubation on 
ice, lysates were clarified by low-speed spin at 18,000 x g for 10 minutes and 
used for immunoblotting for A3G. 
 
A3G Mutant Construction 
Plasmids expressing human A3G were constructed by PCR amplification 
from a construct obtained from Michael Malim (133).  Primers containing the NotI 
and HindIII restriction sites and a single HA tag were used. The PCR product 
was TA cloned into pGEM T Easy Vector (Promega). The sequence was 
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validated and the plasmid (named NotI-hA3G-HA-HindIII) was used as a 
template for all site-directed mutagenesis. The QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene #200523) was used according to manufacturer’s 
protocol.  The following forward and reverse primers were used for the 
construction of C-terminal HA-tagged A3G mutants. C97A A3G F–5’-
CATATCCTGCCCCGCCACAAAGTGTACAAGG-3’ and R–5’-
CCTTGTACACTTTGTGGCGGGGCTCCAGGATATG-3’.  Y124A A3G F–5’-
CTTTGTTGCCCGCCTCGCCTACTTCTGGGACCCAG-3’ and R–5’-
CTGGGTCCCAGAAGTAGGCGCGGGCAACAAAG-3’.  W127A A3G F–5-
CGCCTCTACTACTTCGCGGACCCAGATTACCAG-3’ and R–5’-
CTGGTAATCTGG GTCCGCGAAGTAGTAGCG-3’.  D128K A3G F–5’-
CTACTACTTCTGGAAACCAGATTACCAGG-3’ and R–5’-
CCTCCTGGTAATCTGGTTTCCAGAAGTAGTAG-3’. 
 
Immunostaining and confocal microscopy   
Cells for imaging were grown on 22 mm cover slips in 6-well plates, and 
then fixed with 3.7% formaldehyde for 5 minutes at room temperature.  Cells 
were permeabilized with 0.1% Triton X-100 for 5 minutes.  Permeabilized cells 
were blocked in 5% BSA for 1 hour at room temperature.  Nuclei were stained 
with 1:1000 dilution of To-Pro 3 in PBS for 20 minutes.  For immunofluoresence 
experiments, primary antibodies were diluted in antibody dilution buffer (1% BSA, 
0.05% NP-40, and 2% goat serum in PBS at a concentration of 1:500).  Primary 
antibodies were incubated on cells for 1 hour and the cells washed 3 times with 
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wash buffer (1% BSA and 0.05% NP-40) for 5 minutes. A polyclonal anti-A3G 
antibody (NIH AIDS repository #9968) and HIV-1 anti-p24 mouse monoclonal 
antibody 183 were primary antibodies obtained from NIH AIDS Repository. 
Primary anti-goat antibodies directed against GW182, TIA-1, LAMP3 (CD63), 
and anti-rabbit HA antibody were used; all were obtained from Santa Cruz (Santa 
Cruz, CA).  The Staufen anti-serum was a gift from Dr. Luc DesGroseillers, 
Universite de Montreal. Secondary antibodies used were anti-mouse Alexa Fluor 
546, anti-goat Alexa Fluor 568, and anti-rabbit Alexa Fluor 488 from Molecular 
Probes (Eugene, OR).  Secondary antibodies were diluted in antibody dilution 
buffer at a concentration of 1:1000. Arsenite treatment of cells to induce stress 
granules involved incubation in 1mM NaAsO2  for 30 minutes.  Images were 
acquired using a Carl Zeiss LSM 510 Meta confocal microscope. A3G expression 
plasmids (described above) were transfected into cells without endogenous A3G. 
An HIV-1 Gag construct expressing matrix (MA), spacer peptide 1 (Sp1), capsid 
(CA), nucleocapsid (NC), Sp2, and p6 open reading frames, with CFP fused to 
p6, was used; the construct is competent for pseudo-virion production (38).  
Quantitation of co-localization of A3G and Gag protein was performed by 
thresholding each channel of each image to eliminate nonspecific background 
and the co-localization function of Metamorph (Molecular Devices, Sunnyvale, 
CA) was used to derive percentages of co-localized pixels. 
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Biochemical separation of A3G forms 
A previously validated ultracentifugation method was used to characterize 
the form of A3G in cell cytoplasm (116).   This validation had correlated HPLC-
defined HMM complexes of A3G with A3G in ultracentrifuge pellet fractions and 
the LMM form of A3G with A3G in supernatants after ultracentrifugation.  HeLa 
cells were transfected with the indicated A3G expression plasmid by PEI.  
Confluent 100 mm plates of cells were rinsed with cold PBS, lysed with 500 µL 
cold lysis buffer, and vortexed for 10 minutes.  Cell lysates were clarified at 
17,900 x g for 10 minutes to remove nuclei.  Clarified lysates were 
ultracentrifuged at 45,000 x g for 1 hour at 4°C.  Supernatant fluid was carefully 
removed and the pellet was resuspended in lysis buffer at a volume equal to that 
of the supernatant fluid.  Equal volumes of resuspended pellet and supernatant 
fluid were then subjected to western blot analysis.  Proteins were resolved by 
10% SDS-PAGE.  Proteins were transferred to a nitrocellulose membrane and 
blocked overnight in 5% milk. The membrane was probed with a polyclonal anti-
A3G antibody (NIH AIDS repository #9968) and washed with PBST (0.05% 
Tween 20). 
 
Assessment of intracellular HIV-1 protein decay 
A Gag expression plasmid that generates a myristoylated MA-CA-Sp1-NC 
Gag, lacking Sp2 and p6, was used (MACANC) (83).  This deletes the late 
domain in p6 required for virus budding and allows all expressed Gag to be 
retained intracellularly. Eighteen hours post-transfection with this construct, HeLa 
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cells were either treated or not with 10 µg/ml of cycloheximide.  Cells were lysed 
at 0, 6, 12, and 24 hours post-cycloheximide addition. Lysates were analyzed by 
western blot analysis using the Odyssey LI-COR system (LI-COR, Lincoln, 
Nebraska) to quantitate immunoreactive protein bands. Primary and secondary 
antibodies were incubated with the membrane for 1 hour.  Nitrocellulose 
membranes were blocked overnight at 4° in Odyssey Blocking Buffer.  Blots were 
washed 3 times for 5 minutes with Odyssey blocking buffer (0.05% Tween 20) 
before and after primary and secondary antibody incubation.    HIV-1 Gag 
expression was normalized by β–tubulin for each time point. Secondary 
antibodies anti-mouse IRDye 800 and anti-rabbit Alexa Fluor 680 were used to 
quantitate HIV-1 Gag and β–tubulin respectively following primary antibody 
staining (polyclonal A3G antibody, NIH AIDS repository #9968, and anti-β-tubulin 
primary antibody sc-9104 from Santa Cruz; latter also used in immunoblots). 
 
Viruses and infections 
HIV-1 viral stocks were generated by PEI transfection of HeLa cells with 
15 µg of the infectious (envelope +) molecular clones, pNL4.3, pNL4.3 ∆vif, or 
pNL4.3 vif null.  Similarly, Env- viruses were produced and pseudotyped by co-
transfecting a vesicular stomatitis virus envelope glycoprotein G (VSV-G) 
expression plasmid with either pNL4.3 (env-) or pNL4.3 ∆vif (env-).  3 × 106 
cells/100 mm culture dish were plated 24 hour prior to transfection.  pNL4.3 is a 
full length infectious clone, pNL4.3 ∆vif contains a deletion in vif,  pNL4.3 ∆vif 
(env-) contains an additional deletion of env.  These plasmids were provided by 
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Dr. Chris Aiken.  Both pNL4.3 ∆vif (env+) and pNL4.3 ∆vif (env-) produce a 
truncated nonfunctional Vif peptide of 128 amino acids. pNL4.3 vif null contains 
tandem stop codons at positions 26 and 27 of the vif open reading frame.  
Finally, a HIV-1 viral construct ∆8.9 HIV-1 was also used.  This virus contains 
HIV-1 gag, pol, and rev genes and lacks env and any accessory genes (182). 
Viral supernatants were harvested 48 hours post-transfection.  HIV-1 
capsid protein content was determined using HIV-1 p24 ELISA.  1.5 x 106 CEM 
or CEM-SS cells were infected with 50 ng of p24 containing virus stock.  Four 
hours later, cells were washed three times (to completely remove the input virus), 
resuspended in growth media, and cultured for an additional 24 hours.  Washing 
at 30 minutes after inoculation prevented infection, and served as a control for 
adequacy of washing at 4 hours after inoculation to remove extracellular virions. 
In experiments with infectious (Env+) HIV-1, the non-nucleoside reserve 
transcriptase inhibitor efavirenz (EFV) was added at a concentration of 25 µM at 
16 hours post-infection to limit subsequent rounds of infection.  Viral 
supernatants were ultracentrifuged through a 20% sucrose cushion (125,000 x g 
at 4oC for 45 min.), as previously described, prior to p24 antigen ELISA (41). 
Cellular and viral lysates were prepared and p24 antigen quantified by HIV-1 p24 
antigen ELISA. 
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Results 
A3G only partially co-localizes in HeLa cells with cellular markers for RNA 
granules 
HeLa cells transfected with either A3G-YFP or A3G-HA expression 
vectors displayed both diffuse cytoplasmic staining and localization to large 
cytoplasmic puncta (Fig. 2-1A). Further analysis indicated that A3G-YFP partially 
co-localized with protein markers for several RNA granules including P-bodies 
(GW182) and Staufen granules (Staufen) (Fig. 2-1B). The number of P-bodies 
present in cells did not differ with and without A3G-YFP transfection. Fifty fields 
using the middle slices of confocal z-sections were chosen, using Dcp1 as a 
marker for P-bodies. From those 50 fields, 30 fields were randomly selected for 
quantitation.  There were 5 ± 2 P-bodies per cell without A3G-YFP transfection 
and 6 ± 2 P-bodies per cell with A3G-YFP transfection. Stress granules were not 
seen in HeLa cells after A3G transfection; arsenite treatment was necessary to 
induce stress granules. A3G co-localized with TIA-1 in arsenite-induced stress 
granules (Fig. 2-1B). Potential dynamic transit among structures was also 
suggested by lack of co-localization of A3G with the late endosome marker CD63 
at 16 hours and partial co-localization with that marker at 24 hours (Fig. 2-1C). 
Thus, A3G partially co-localizes with P-bodies and or Staufen granules, stress 
granules (if present after stress), and late endosomes. However, A3G complexes 
do not appear to be identical to any of these cytoplasmic structures.  These 
complexes have been observed by many and are not dependent on 
overexpression of A3G (Fig. 2-2). 
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 Figure 2-1. A3G only partially co-localizes in HeLa cells with cellular markers for RNA granules.  
A. shows confocal images of Hela cells transfected with A3G-YFP and A3G-HA. B. shows HeLa 
cells transfected with A3G-YFP and stained with antibodies for Staufen, GW182, and TIA-1 
shown in red. C. HeLa cells transfected with A3G-YFP and stained with antibodies to the late 
endosome marker, CD63. The top row of Panel C are cells 16 hours post-transfection and the 
bottom row of Panel C are cells at 24 hours post-transfection. All nuclei are stained with To-Pro3. 
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HIV-1 Gag co-localizes with A3G complexes 
To test whether these A3G complexes also co-localize with HIV-1 Gag, 
HeLa cells were co-transfected with HIV-1 Gag-CFP and A3G-YFP expression 
constructs.  The Gag-CFP vector is competent for HIV-1 virus-like particle 
production (38).  After 16 or 24 hours, cells were fixed and immunofluorescence 
images were taken (Fig. 2-3A).  The 16 hour post-transfection time-point was 
selected because it maximizes intracellular Gag levels before large amounts of 
Gag are found at the plasma membrane.  A3G and Gag co-localized at 16, but 
not 24, hours after co-transfection (Fig. 2-3A, top and middle rows). Gag 
localization was not affected by co-transfected A3G (Fig. 2-3A, comparing lower 
row with Gag transfected alone to top and middle rows with co-transfected Gag 
and A3G).  HIV Gag is seen at the plasma membrane by 24 hours with or without 
A3G transfection, Fig. 2-3A.  Areas of co-localization (yellow) were quantified in 
30 randomly selected images using Metamorph software.  Approximately 29% of 
A3G pixels overlap with those of Gag, while 31% of Gag pixels overlap with 
those of A3G.  The CD63 late endosome marker that did not co-localize with 
A3G at 16 hours (as seen in Fig. 2-1C) was used as a negative control in Fig. 2-
3B.  
 
C97A A3G has delayed A3G complex formation 
I studied several A3G mutants that varied in their ability to be packaged 
into the virion.  I used confocal microscopy and biochemical fractionation to 
determine their subcellular localization.  All A3Gs were HA-tagged.  D128K and 
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C97A A3G are each packaged efficiently into virions (110, 130).  D128K A3G 
alters species specificity for Vif, allowing degradation by SIV agm Vif but not HIV-
1 Vif (18, 82, 130, 168).  C97A A3G alters the first zinc-finger domain, is 
monomeric in biochemical assays, and maintains Vif-sensitive antiviral activity 
(109). Y124A and W127A A3G are each severely deficient in virion packaging 
(64). 
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Figure 2-2. A3G complex formation.  Confocal micrographs show HeLa cells transfected with 
varying amounts of A3G-YFP.  0.12, 0.25, and 0.50 µg of A3G-YFP plasmid DNA were 
transfected into HeLa cells.  Cells were fixed and imaged 24 hours post-transfection for A3G-YFP 
(green).  A3G complexes are observed in all conditions, indicating the ability of A3G complexes to 
form even when A3G is expressed at low levels. 
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 Figure 2-3. HIV-1 Gag Co-localizes with A3G-complexes. A. shows cells cotransfected with A3G-
YFP (green) and HIV-1 Gag-CFP (125) or Gag-CFP alone in the bottom row at the indicated time 
point post-transfection. B. quantitates co-localization of A3G-YFP and Gag-CFP in cotransfected 
cells in 30 fields that were randomly selected from 50 fields for quantitation. As a control, cells 
transfected with A3G-YFP and stained with anti-CD63 antibody at 16 hours (before A3G co-
localizes with CD63, Fig. 2-1, panel C) were also used. Error bars represent standard deviation. 
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 Figure 2-4A. C97A A3G fails to form complexes at 24 hours. A. HeLa cells were transfected with 
the indicated A3G-HA construct (either D128K, C97A, Y124A, Y127A or wild-type A3G-HA) and 
then imaged by staining with anti-HA antibody at 24 hours post-transfection.   
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 Figure 2-4B. C97A A3G fails to forms A3G complexes at 24 hours. B. Cell lysates of transfected 
cells from the same experiment as A. were subjected to ultracentrifugation at the same 24 hour 
time point after transfection.  The pellet and supernatant were subjected to western blot analysis 
and the blot imaged by incubation with an anti- HA antibody. The amount of A3G in the pellet (P) 
and supernatant (S) of transfected cells are shown in the upper panel. The middle panel shows 
the same samples run on a SDS-PAGE gel and stained with coomassie as a loading control. The 
lower panel provides a key to indicate which A3G-HA construct is in each lane in the upper and 
middle panels. 
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 Figure 2-5. C97A A3G forms A3G complexes at 48 hours.  HeLa cells were transfected 
with C97A A3G-HA and cells were either imaged or lysates generated and analyzed by 
ultracentrifugation.  A. shows confocal images of HeLa cells transfected with C97A A3G -
HA and visualized at 48 hours post-transfection.  Two representative images are shown 
that indicate variation in complex formation at 48 hours post-transfection.  B. shows 
lysates from C97A A3G-HA transfected HeLa cells 48 hours post-transfection.  C97A 
A3G -HA is seen in both the pellet and supernatant fractions indicating the presence of 
A3G complexes at 48 hours. 
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Each of these C-terminal HA-tagged A3G constructs was transfected 
individually into HeLa cells to determine their ability to make A3G complexes.  
Cells were fixed at 24 hours post-transfection and stained with anti-HA antibodies 
to detect the various A3Gs.  Fig. 2-4A shows that WT A3G-HA formed bodies at 
24 hours. All A3G mutants formed bodies similar to that of wild-type, except 
C97A A3G-HA.  C97A A3G-HA was more diffuse throughout the cytoplasm at 24 
hours after transfection than the other A3Gs studied.  C97A A3G-HA also 
displayed increased nuclear staining at that time, relative to the other A3Gs 
studied (Fig. 2-4A). 
Ultracentrifugation of cytoplasmic lysates following removal of nuclei 
showed that D128K, Y124A, W127A, and WT A3G proteins each were present in 
both the pellet and the supernatant (Fig. 2-4B).  In contrast, C97A A3G-HA was 
only detected in the supernatant (lanes 4, Fig. 2-4B) and not detected in the 
pellet (lane 3, Fig. 2-4B).  This biochemically confirmed the absence of A3G 
complexes in C97A A3G-HA observed by confocal imaging at 24 hours (Fig. 2-
4A).  As a control for equivalent protein loading, the Coomassie blue-stained gel 
of the cytoplasmic lysate pellets shows similar protein amounts in the pellet of 
each mutant including C97A-HA (Fig. 2-4B, middle panel). The C97A mutant 
does form some complexes at 48 hours post-transfection, Fig. 2-5.   
 
C97A A3G is packaged into virions at 24 hours 
HeLa cells were transfected with the ∆8.9 HIV construct and constructs 
expressing wild-type A3G-HA, D128K, C97A, Y124A, or W127A.  Twenty four 
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hours post-transfection clarified culture supernatant fluids were filtered and 
ultracentrifuged through a 20% sucrose cushion to concentrate pseudo-virions 
produced from the co-transfected cells.  Both cell and pseudo-virion lysates were 
subjected to western blot analysis.  
Cell lysates showed that equal amounts of A3G were produced in all 
transfected cells (Fig. 2-6B). The Y124A and W127A A3G mutants were not 
detected in pseudo-virion lysates, consistent with previous report (Fig. 2-6A) (64).  
At 24 hours post-transfection, the C97A A3G mutant was present in particles, as 
was WT A3G, and D128K A3G (Fig. 2-6A). These results confirm earlier reports 
of the packaging of C97A.  These results are consistent with A3G complexes not 
being the source of packaged A3G as others have suggested based on different 
experimental strategies (109, 110, 145).  Therefore, co-localization of Gag in 
A3G complexes does not suggest the complexes are involved in the process of 
virion assembly, as would be suggested if A3G was packaged from complexes. 
 
Producer cell A3G complexes decrease HIV-1 pseudo-virus production and 
intracellular HIV-1 Gag half-life 
I next sought to compare levels of HIV-1 production from cells with and 
without A3G complexes to test whether virus production was decreased in cells 
containing complexes.  HeLa cells were co-transfected with ∆8.9 HIV-1 and 
either an empty vector control, WT A3G-HA, C97A A3G-HA or Y124A A3G-HA.  
After 24 hours, culture supernatant fluids and cellular lysates were collected and 
HIV-1 p24 antigen ELISA and western blots were performed.  Culture 
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supernatant fluids were centrifuged at low speed to remove cellular debris, 
filtered, and ultracentrifuged through a 20% sucrose cushion to concentrate 
pseudo-virions containing CA.  The concentration of p24 antigen in the pellet of 
the ultracentrifuged culture supernatant was divided by the sum of the amount of 
p24 antigen reactivity in the cell lysate plus the pellet of the ultracentrifuged 
culture  
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 Figure 2-6. C97A A3G is packaged into virions at 24 hours.  HeLa cells were transfected with the 
env-deleted 8.9 HIV-1 construct and the indicated A3G-HA DNA construct (WT, D128K, C97A, 
Y124A, Y127A). 24 hours post-transfection, cells and supernatants were harvested and cell 
lysates prepared. The supernatants were filtered and ultracentrifuged through a 20% sucrose 
cushion. The resulting pellet was resuspended in a volume equal to that of the cell lysate. A. 
shows western blots of the viral lysates. B. shows western blots of the cell lysates. Blots are 
visualized by staining with the antibodies shown at the right of each gel (anti-HA antibody, anti-
HIV-1 p24 antibody, and anti-tubulin antibody). 
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supernatant to yield the percent p24 antigen produced. The amount of p24 
antigen produced from HeLa cells co-transfected with HIV-1 and a control empty 
vector was comparable to similar experiments reported by others (49, 56, 152). 
Cells co-transfected with the control plasmid not expressing A3G, as well 
as the plasmid expressing C97A A3G-HA that did not form A3G complexes at 24 
hours, each released significantly more pseudo-virions than did cells co-
transfected with WT A3G-HA or Y124A A3G-HA (Fig. 2-7A).  Both A3G-HA and 
Y124A A3G-HA form A3G complexes at 24 hours, Fig. 2-4A. A3G levels in the 
cells containing each A3G variant were similar based on anti-HA staining, and 
anti-β–tubulin staining also controlled for similar loading of each specimen 
(Figure 2-7B). To determine whether the levels of A3G in transfected HeLa cells 
were within the range of endogenous A3G expression in T cells, cell lysates of 
CEM cells (which express endogenous A3G), WT A3G-HA-transfected HeLa 
cells (from the experiments depicted in Fig. 2-7 A & B), and activated primary 
CD4+ T cells (derived from peripheral blood mononuclear cells of a donor not 
infected with HIV-1) were immunoblotted using an anti-A3G antibody (Fig. 2-7C). 
The level of exogenous A3G in the transfected HeLa cells was not higher than 
that of endogenous A3G in CEM cells and activated primary CD4+ T cells (Fig. 2-
7C, normalized for β-tubulin), indicating that there was not supra-physiologic 
over-expression of A3G.   
Cells expressing either WT A3G-HA or Y124A-HA had 28% and 34% of 
the pseudo-virus output, respectively, compared to control cells lacking A3G (for 
each, p<0.0079, in both cases, Mann-Whitney U) (Fig. 2-7D). Cells containing 
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the C97A-HA mutant, that does not produce A3G complexes at 24 hours, did not 
differ from the A3G-negative control (Fig. 2-7D).  The amount of intracellular HIV-
1 p24 antigen did not differ between A3G-negative cells and WT A3G-HA- and 
C97A-HA-containing cells (Fig. 2-7D).   
If A3G complexes were only blocking release of assembled pseudo-
virions, an increase in intracellular p24 antigen would be expected to accompany 
decreased supernatant p24 from cells containing A3G complexes. The lack of 
such an increase in intracellular p24 suggested that A3G complexes may 
decrease intracellular HIV-1 levels rather than directly affecting only virion 
release.  The rate of HIV-1 Gag degradation in HeLa cells was therefore studied 
after protein synthesis was blocked by cycloheximide. A Gag variant that is not 
released from cells because of a p6 late domain deletion was used for this 
experiment to avoid confounding differences in pseudo-virus release.  Gag levels 
were compared over time in cells expressing p6-deleted Gag alone, p6-deleted 
Gag with WT A3G (forming complexes), and p6-deleted Gag with C97A A3G (not 
forming A3G complexes) (Fig. 2-7E).  Cells were treated with 10 µg/ml of 
cycloheximide 18 hours post-transfection. Cells were collected and lysed at 0, 6, 
12, and 24 hours following start of cycloheximide treatment.  Gag protein level 
was normalized by β–tubulin immunoreactivity at each time point. There was no 
difference in Gag expression between cells with A3G and those without at time 
point 0 (Fig. 2-7E). β–tubulin expression did not change over time (not shown).  
Multiple linear regression showed Gag levels increased over time in cells left 
untreated as a control.  Multiple linear regression also showed that HIV-1 Gag  
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Figure 2-7A-D. Producer cell A3G complexes decrease HIV-1 pseudo-virus production and 
intracellular HIV-1 Gag half-life. A. The percentage of HIV-1 p24 antigen production 24 hours 
after HeLa cells were co-transfected with ∆8.9 HIV-1 and the indicated A3G expression plasmid 
construct (control = empty A3G expression vector) are shown. B. The table shows average p24 
values from cell lysates and supernatants of the experiment in Fig. 5A.  There is a significant 
difference in supernatant (P = 0.0079, in both cases, Mann-Whitney U) and total p24 levels (P < 
0.0079, in both cases, Mann-Whitney U) between the no-A3G control and the A3G and Y124A 
conditions. Significant differences in percentage HIV-1 p24 antigen production from the no-A3G 
control are indicated by an asterisk (P < 0.0079 in each case, Mann Whitney U). C. Western blots 
of the cell lysates from Panel A are shown indicating equivalent amounts of: A3G for each variant 
(based on anti-HA staining, upper panel); HIV-1 Gag (middle-panel); and protein loading (based 
on anti-β-tubulin antibody staining, lower panel). Cells were co-transfected with ∆8.9 HIV-1 and: 
Lane 1. control empty-vector; Lane 2. A3G-HA; Lane 3. C97A A3G-HA; and Lane 4. Y124A A3G-
HA.  D. Western blot shows relative A3G levels in: Lane 1. CEM cells; Lane 2. A3G-transfected 
HeLa cells; and Lane 3. activated CD4 T cells.  
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Figure 2-7E. Producer cell A3G complexes decrease supernatant HIV-1 pseudo-virus production 
and intracellular HIV-1 Gag half-life. E. Cycloheximide blocking experiment showing HIV-1 Gag 
half-life over 24 hours following 10 µg/ml treatment at 0 hours.  Degradation of p24 was assessed 
by quantitative immunoblot after protein synthesis inhibition by cycloheximide, in the presence or 
absence of A3G complexes. Controls were treated similarly, but with no cycloheximide treatment.  
Cells were lysed at the indicated time point and subjected to western blot analysis and bands 
quantitated using Odessey Licor.  HIV-1 Gag was normalized to β–tubulin.  Multiple Linear 
Regression analysis showed that cells with wild-type A3G declined in their HIV-1 Gag expression 
more rapidly than cells with no A3G, p = 0.009.  There was no difference in Gag levels between 
cells with no A3G versus those with C97A, p= 0.8. There was no statistical difference in Gag 
expression between cells with A3G and those without at time point 0, p = 0.6. 
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Figure 2-8.  Cycloheximide does not inhibit A3G complex formation. The above images show 
HeLa cells transfected with A3G-HA and treated with 10 µg/ml of cycloheximide for 24 hours.  
After the 24 hour treatment, cells were fixed and stained for A3G using anti-HA antibody.  A3G 
complexes are still observed following cycloheximide treatment. 
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levels decreased more rapidly after cycloheximide addition in cells with A3G 
complexes (WT A3G-transfected cells) than in cells with either no A3G or C97A 
A3G that does not form A3G complexes (p = 0.009).  There was no difference 
between treated cells with C97A and those with no A3G.  Cycloheximide 
treatment alone does not abrogate A3G complex formation, Fig. 2-8.  Based on 
these data I hypothesize that A3G complexes shorten HIV-1 Gag protein half-life. 
 
CEM cells depleted of endogenous A3G by Vif produce more HIV-1 virions 
than do A3G-containing CEM cells 
I next sought to confirm that this effect of A3G complexes to decrease 
HIV-1 production was not an artifact of over-expression, exogenous expression, 
or virus transfection. I determined whether this A3G-mediated restriction would 
be seen in more physiological conditions: a single-replication cycle HIV-1 
infection of a T cell line, CEM that expresses physiological levels of endogenous 
A3G (Fig. 2-9C). I hypothesized that Vif expressed from WT NL4.3 HIV-1 would 
degrade A3G both within and outside of A3G complexes, while cells infected with 
Vif-negative NL4.3 would have unaltered levels of A3G complexes.  This allows a 
comparison of relative virus output from the same HIV-1- infected producer T cell 
type in the presence and absence of endogenous A3G, including A3G 
complexes. I limited virus replication to a single round to avoid possible 
confounding effects of multiple rounds of replication. 
I first studied CEM cells infected with VSV-G envelope-pseudotyped HIV-1 
that could not cause a spreading infection, and then assessed fully replication-
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competent viruses with CXCR4-tropic HIV-1 envelopes. With both types of 
envelopes, HIV-1 replication was limited to a single round. EFV was added at 16 
hours after infection with CXCR4-tropic HIV-1 envelope positive proviral clones to 
limit secondary rounds of replication in that experiment.  A control experiment 
where 25 µM EFV was added at the time of infection confirmed that this 
concentration prevented viral replication, with no toxic effect on cell numbers or 
cell viability (data not shown).  The VSV-G pseudotyped viruses were NL4.3 env-
deleted strains, with either a wild-type or a deleted (∆vif) gene. In addition to wild-
type, Vif-positive NL4.3, two different Vif-negative HIV-1 strains were used in the 
experiments with HIV-enveloped viruses: NL4.3 ∆vif and NL4.3 vif null.  NL4.3 
∆vif is an isogenic clone of pNL4.3 with an in-frame deletion in vif resulting in a 
128 amino acid protein that is inactive but incorporated into virions.  NL4.3 vif null 
is an isogenic clone of pNL4.3 that contains tandem stop codons at residues 26 
and 27 of the vif open reading frame.  I also infected CEM-SS cells that lack any 
A3G protein, as another control to determine if results were specifically related to 
A3G (133). Culture supernatants were cleared of debris and virions 
ultracentrifuged through a 20% sucrose cushion before p24 antigen ELISA was 
done. As in the experiments in Fig. 2-7, the p24 content of the ultracentrifuged 
culture supernatant was divided by the sum of the amount of p24 antigen 
reactivity in the cell lysate plus the pellet of the ultracentrifuged culture 
supernatant to yield the percent p24 antigen release from the producer cell. 
The percentage of p24 antigen production was decreased from CEM cells 
infected with a Vif-negative, VSV-G-pseudotyped NL4.3 compared to an 
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otherwise isogenic Vif-positive virus at 24 hours post-infection (Fig. 2-9A; two left 
bars; p< 0.0022, Mann-Whitney U).  In addition, decreased HIV-1 production was 
observed from CEM cells infected with either of two CXCR4-tropic, HIV-
enveloped Vif-negative viruses (∆vif and vif null), relative to a Vif-positive HIV-1 
(Fig 2-9B; left three bars; p = 0.005 at each time point). A3G was detected only in 
the Vif-negative virus infections (lower panel in Fig. 2-9 A & B), with β–tubulin 
immunoreactivity indicating similar protein loading in each lane. A3G was present 
in cell lysate ultracentrifugation pellets indicating the presence of A3G complexes 
in CEM cell lysates transfected with NL4.3 ∆vif and NL4.3 vif null (Fig. 2-9C).  No 
A3G complexes, defined as A3G in ultracentrifugation pellets, were observed in 
CEM cells infected with Vif-positive NL4.3; no A3G was detected in cell lysate 
ultracentrifuge supernatants either (Fig 2-9C).  A Coomassie blue-stained gel 
showed equivalent protein loading in all lanes of Fig. 2-9C (not shown). HIV-1 
production from CEM-SS cells lacking any A3G did not differ at 24 hours after 
infection with Vif-positive versus Vif-negative viruses (Fig. 2-9 A & B, right hand 
bars). The amount of intracellular p24 detected in cell lysates was similar across 
all viruses and cells at 24 hours (Fig. 2-9D); amounts of HIV-1 p24 antigen were 
decreased in the pelleted supernatant, as seen previously in Fig. 2-7.  This again 
is consistent with A3G complexes having an effect on intracellular levels of HIV-1 
Gag protein, and not directly affecting release of virions from the cell.  When 
percent production was calculated relative to wild-type, Vif-positive HIV-1, VSV-G 
pseudotyped NL4.3 ∆vif produced 44% of the wild-type amount from CEM cells 
(Fig. 2-9D).  Again no difference was observed in CEM-SS cells between VSV-G 
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pseudotyped viruses with or without HIV-1 Vif.  The same effect was seen with 
Env+ viruses, as the Vif-deleted viruses produced 51% and 47% of the amount 
from CEM cells infected by WT, Vif-positive NL4-3 that were depleted of A3G (p 
< 0.002, Mann-Whitney U; Fig. 2-9D).   
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Figure 2-9 A-B. CEM cells depleted of endogenous A3G by Vif produce more HIV-1 virions than 
do A3G-containing CEM cells.  A. shows single-round infections of Env- virus at 24 hours post-
infection.  Control is the VSV-G pseudotyped, vif-positive NL4.3-infected CEM cells that were 
washed at 30 minutes after infection. Lanes 1 and 3 are cellular lysates from CEM and CEM-SS 
cells infected with NL4.3 respectively.  Lanes 2 and 4 are cellular lysates from CEM and CEM-SS 
cells infected with ∆vif  NL4.3 respectively.  B. shows single-round infections of replication-
competent CXCR4-tropic HIV-1 Env+ virus at 24 hours post-infection. The left bars represent 
percent virus production from CEM cells and the right bars represent percent virus production 
from CEM-SS cells. Lanes 1 and 4 are cellular lysates from CEM and CEM-SS cells infected with 
NL4.3 respectively.  Lanes 2 and 5 are cellular lysates from CEM and CEM-SS cells infected with 
∆vif  NL4.3 respectively.  Lanes 3 and 6 are cellular lysates from CEM and CEM-SS cells infected 
with vif null NL4.3 respectively.  Means of 6 replicates are presented in the graphs. Error bars 
represent standard deviation. The decrease in % p24 release from the vif-deleted virus, relative to 
the vif- positive viral control, in CEM cells was significant (A. P = 0.0022, Mann-Whitney U) (B. P 
= 0.005 in all cases, Mann-Whitney U).  No difference in virus production between the vif-positive 
and vif-deleted virus constructs was seen in CEM-SS cells. 
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Figure 2-9C-D. CEM cells depleted of endogenous A3G by Vif produce more HIV-1 virions than 
do A3G-containing CEM cells.  C. The table shows that the amount of HIV-1 p24 antigen in cell 
lysates infected with all viruses were similar at each time point; differences were seen only in 
supernatant p24 antigen amounts in CEM cells. Total p24 was lower in cells with A3G complexes.  
The CA-182 capsid monoclonal antibody recognizes both full length and processed forms of 
Capsid protein. There was no significant difference in HIV-1 p24 antigen production between vif 
positive and either vif defective virus at any time point in CEM-SS cells. Significant decreases in 
percentage HIV-1 p24 antigen production, compared to the vif-positive virus, are indicated by an 
asterisk.  D. depicts ultracentrifugation of CEM cell lysates from the experiment in Panel B. and 
indicates that the vif-positive virus depleted A3G-complexes (found in the pellet, P) as well as the 
A3G found in the supernatant (S). 
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Discussion 
My results demonstrated that cytoplasmic A3G complexes decrease HIV-1 
virion production in a physiological system.  Much of the cytoplasmic A3G in cell 
lines and activated primary T-lymphocytes is present in such complexes.  I found 
that A3G only partially co-localizes with markers for RNA granules.  A3G 
complexes also only partially associates with stress granules; indeed, stress 
granules were not present until after arsenite-induced cellular stress (32, 53, 54, 
78, 94).  Others have also found, as I did, that A3G expression does not induce 
P-bodies or stress granules (54). These findings, as well as the partial co-
localization of A3G with the CD63 marker of late endosomes only at later time 
points after transfection, led us to conclude that A3G is dynamic and not 
exclusively localized to a single RNA granule / cytoplasmic compartment. Earlier 
reports also indicated that A3G’s cytoplasmic location changes over time and 
that it traffics between compartments / RNA granules (25, 30, 45, 53, 73, 78, 94, 
156).  There is also consensus that there is a dynamic interaction among RNA 
granules in that they exchange many of their components (101, 147).  My results 
are also consistent with the view that A3G complexes may not be identical with 
only one previously described type of RNA granule.  
Because about 30% of HIV-1 Gag and A3G co-localized with each other 
(Fig. 2-3B), I speculated that A3G complexes may be the cytoplasmic source 
from which A3G gained access to assembling virions.  An earlier report also 
suggested this (159).The hypothesis that A3G complexes may play a role in 
virion assembly is also consistent with data that P-bodies are required for 
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replication of Ty1 and Ty3 retrotransposons in yeast; indeed, human A3G has 
been localized to P-bodies when over-expressed in yeast (11, 45).  Results 
presented here, however, are consistent with two prior lines of evidence 
indicating that the co-localization of A3G in cytoplasmic structures is not required 
for HIV-1 virion assembly and release. Opi, et al. previously reported, as I also 
observed, that C97A A3G did not form cytoplasmic bodies within 24 hours post-
transfection and had greater nuclear localization than wild-type A3G (109, 110). 
Despite some differences in methodology, the concordance of results between 
the present study and Opi, et al. (109) conclusively indicate that C97A A3G is 
packaged into virions. Soros, et al. presented a separate line of evidence about 
the role of A3G complexes in virion packaging of A3G (138). Using pulse-chase 
radio-labeling, Soros, et al. showed that newly-synthesized A3G was packaged 
into virions, prior to the time required to observe complex formation. Their 
methodology did not allow exclusion of the possibility that virion packaging 
occurred from very recently assembled complexes. However, the present study 
indicates that C97A A3G packaging occurs in the absence of microscopically 
visible cytoplasmic bodies containing A3G.    
A3G complexes have been implicated in A3G’s inhibitory effects against 
retrotransposons (32, 63), leading us to explore if there was a functional effect of 
A3G complexes on HIV-1 replication.  I started with a genetic analysis of A3G 
effects on pseudo-virion production and then used a more physiological 
approach to exclude that results were an epiphenomenon or artifact of A3G over-
expression. 
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I compared HIV-1 production in the presence of wild-type A3G versus 
different mutant A3Gs, after confirming that C97A A3G had delayed A3G 
complex formation in HeLa cells (109, 110). HeLa cells that lack endogenous 
A3G were co-transfected with a non-infectious, env-deficient HIV-1 genome and 
a vector expressing either wild-type A3G, C97A A3G, Y124A A3G, or a control 
expression plasmid lacking A3G. HIV-1 virion production was reduced over 
three-fold in a single-round of replication from cells with wild-type A3G and 
Y124A A3G, which each form A3G complexes.  In contrast, cells containing 
C97A A3G lacked biochemical evidence of A3G complexes at 24 hours, and 
released higher levels of HIV-1 p24 antigen; levels were similar to that seen from 
control-transfected cells lacking A3G (Fig. 2-7).  While another difference 
between C97A A3G and the other A3G proteins studied that is unrelated to 
formation of A3G complexes in the cytoplasm cannot be excluded, the difference 
between the empty vector control and both wild-type A3G and Y124A A3G 
indicates that the observed reduction of particle production is A3G-specific.  
One surprising aspect of the results in Fig. 2-7 was that intracellular HIV-1 
Gag levels were not increased in the presence of A3G complexes, as would be 
expected if the complexes provided a direct block to virion release. This led us to 
test the hypothesis that intracellular HIV-1 Gag protein levels may be decreased 
in the presence of A3G complexes by following Gag protein levels after 
cycloheximide inhibition of protein synthesis. A late domain-deleted Gag that 
blocks Gag release by budding from membranes was used to limit analysis to 
study of intracellular Gag. Results showed that a more rapid decrease in 
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intracellular HIV-1 Gag levels following protein synthesis inhibition was 
associated with the presence of A3G complexes (Fig. 2-7E). This finding strongly 
suggests that the effect of A3G complexes to decrease HIV-1 production occurs 
at a step in replication prior to release of budding virus from the membrane. 
I next sought to confirm that inhibitory effects of A3G complexes on HIV-1 
production were not related to other effects of A3G mutations, exogenous A3G or 
A3G over-expression by using a different experimental strategy. I studied single-
round infections of enveloped HIV-1 particles, with and without an intact vif open 
reading frame. This approach was intended to compare cells depleted of 
endogenous A3G by vif-positive infection with those retaining A3G, including 
complexes, after vif-defective virus replication. I tested viruses with VSV-G 
envelopes that were capable of only a single round of replication, as well as 
different viruses with CXCR4-tropic HIV envelopes. Inhibition of a second round 
of replication was achieved for the latter replication-competent viruses by adding 
a non-toxic, non-nucleoside reverse transcriptase inhibitor at 16 hours after 
infection. These experiments included two different types of vif-defective viruses. 
One vif-defective virus generates a truncated, non-functional Vif; the other vif-
defective virus has tandem stop codons in the vif reading frame at positions 26 
and 27. This therefore also allowed us to exclude that my results were not due 
only to lack of an HIV-1 envelope, or use of one particular vif-deleted HIV-1 
variant. 
CEM cells infected with either of the two strains of vif-defective HIV-1, 
whether pseudotyped by VSV-G or HIV-1 envelope, produced significantly less 
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HIV-1 p24 antigen into the supernatant than did CEM cells infected with the Vif-
positive HIV-1 (Fig. 2-9). The wild-type Vif-positive virus degraded endogenous 
A3G that was diffuse in the cytoplasm as well as in A3G complexes in these 
CEM cells (Fig. 2-9C).  CEM-SS cells contain no endogenous A3G; no difference 
in virion production was seen in the comparison of Vif-positive and Vif-defective 
HIV-1 from CEM-SS cells (Fig. 2-9 A & B). Vif-induced A3G degradation in CEM 
producer cells restored virus production to the higher levels that were seen in 
A3G-negative CEM-SS cells. Again, results indicate decreased HIV-1 production 
that is specific for the presence of A3G complexes.  
In summary, I have identified that HIV-1 virion production is diminished 
from cells containing A3G complexes, and suggest that this is not due to an 
effect on release of budding virions from the plasma membrane.  My results 
suggest that a mechanism for the decreased HIV-1 production observed here is 
that A3G complexes decrease the intracellular levels of HIV-1 Gag needed for 
virion assembly. This could be due to a process that moves A3G complexes and 
associated HIV-1 Gag into late endosomes, and then lysosomes for degradation. 
HIV-1 Gag has been shown by others to significantly co-localize with CD63 at 
times after 12 hours (42); A3G was identified here to have delayed partial co-
localization with late endosomes. It is also possible that A3G complexes 
decrease the availability of HIV-1 mRNA for translation, as occurs in P-bodies 
(102). However, some evidence indicates that A3G has the opposite effect (e.g., 
shuttling of cellular mRNAs from P-bodies to polysomes), although HIV-1 mRNAs 
were not studied in that paper (78). Further experimentation will be needed to 
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define the cellular post-transcriptional mechanism underlying the more rapid 
decrease in Gag levels following protein synthesis inhibition seen here, however. 
The possibility that the antiviral effect of A3G complexes in the producer cell 
extends to other retroviruses also warrants study.   
These results reveal a novel anti-HIV activity of A3G within the producer 
cell.  Until now, it was thought that A3G only exerted its antiviral effect in the 
target cell following packaging into virions in the producer cell.  The magnitude of 
this previously unrecognized anti-HIV activity of A3G in producer cells was 
modest. However, I performed only single-round replication experiments because 
this was the only way to isolate a potential effect of producer cell A3G from the 
effects of virion-packaged (and possibly target cell) A3G that would be seen in a 
spreading infection. The multiple rounds of infection that occur in vivo will likely 
enhance the effect of A3G complexes to decrease HIV-1 production. Another 
factor is that other A3s that are expressed in T-lymphocytes and present in 
cytoplasmic bodies, such as A3F (53), may have similar activity as that 
characterized here for A3G, and further decrease virion output from producer 
cells. Some cells that produce HIV-1 virions in vivo contain higher physiological 
levels of A3G, and A3F, than others (51, 52). In addition, NL4-3 Vif is relatively 
active in A3G degradation in vitro, compared to Vif from other HIV-1 strains 
including some derived from in vivo specimens (135). My results raise the 
possibility of increasing cellular A3G expression, and possibly that of other A3s, 
to reduce virion output from producer cells, as well as the previously described 
antiviral mechanisms that diminish virion infectivity and target cell infection. The 
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functional relevance of our observation would be enhanced if decreased virion 
production synergized with increased virion packaging of A3G. This investigation 
is underway and requires a different experimental approach than used here.  In 
addition, the present work suggests that further characterization of the 
interactions of RNA granules and endosomes with A3G and Gag will illuminate 
both cellular and HIV-1 biology, particularly mechanisms of post-transcriptional 
control of HIV-1 expression that are not yet fully characterized. 
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CHAPTER III 
 
Restriction of the Late Steps of HIV-1 Replication by A3G Complexes and 
mRNA Processing Bodies in Producer Cells 
 
 
Introduction 
 
In HIV-1 Vif-deficient strains, A3G (A3G) is incorporated into progeny 
virions (35, 84, 177).  This results in the production of HIV-1 virions with 
significantly reduced infectivity because reverse transcription and integration are 
restricted in the target cell (61).  HIV-1 Vif normally acts to target A3G for 
proteasomal degradation, thereby dramatically reducing cellular levels of A3G 
available for viral packaging (167, 175).  A3G is found in two major forms in cells: 
the low molecular mass (LMM) form and high molecular mass (HMM) complexes 
(57, 79, 137).  The LMM form is diffuse throughout the cytoplasm as seen by 
confocal microscopy and is the form packaged into virions.  HMM complexes are 
observed as large cytoplasmic bodies called A3G complexes here.   
A3G complexes contain many cellular proteins and RNAs; including motor 
proteins, ribosomal subunits, helicases, translation factors, and scaffold proteins 
(32, 159).  These protein components resemble the constituents of cellular 
structures known as RNA granules (7, 73, 147, 164).  Indeed, confocal 
microscopy confirms the colocalization of many protein markers RNA granules 
with A3G complexes (164).  Others have used A3G as a marker for mRNA 
processing bodies (P-bodies) (102).  P-bodies are cytoplasmic structures in 
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which RNA silencing occurs via microRNAs (miRNA) and other components of 
the RNA-induced silencing complexes (RISC).  However, characterization of the 
proteins essential for structure and functions of RNA granules, including P-
bodies, is ongoing. 
Components of miRISC are proteins of the Argonaut family (Ago1 to 
Ago4) that are required for miRNA-mediated silencing. A key factor in this 
process is the GW182 protein that interacts directly with Ago proteins to 
orchestrate mRNA decapping. It also is thought to recruit RCK/p54 (DDX6) that 
regulates the activity of the 5’ decapping enzymes DCP1/DCP2, and 3’ mRNA 
deadenylation. mRNA decapping and deadenylation leads to mRNA decay 
through the action of XRN1, a 5'-3' exonuclease. RNAi effectors, including 
miRNAs and their target mRNAs, Ago proteins, GW182, RCK/p54, LSm-1 and 
DCP proteins co-localize in cytoplasmic structures called GW-bodies or P-bodies 
GW-bodies were recently proposed to be GW182-rich RNA granules associated 
with endosomes, and to be distinct from P-bodies with which they were 
previously grouped.  P-bodies are now proposed to be a distinct GW182-poor 
pool of RNA granules It is unclear whether A3G complexes are distinct structures 
from RNA granules (136).  In the cell, A3G complexes have been shown to 
restrict the retrotransposition of Alu (32, 63).  Yet, they are required for the 
assembly of certain retroelements such as TY1 and TY3 (27, 45).  Recent 
characterization of poliovirus disruption of P-bodies added to understanding of 
the scaffolding/formation of these structures, and also raised questions about 
whether GW182 was essential for P-body formation (43). Thus, I sought to 
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further investigate whether GW182 and RCK/p54 were each required for A3G 
complexes to form and function. 
Until now, the role of these complexes in the HIV-1 viral lifecycle was not 
known.  Recent reports suggest that P-bodies are necessary for formation of 
infectious HIV particles, based on the reduced virus production and infectivity 
seen with perturbation of a P-body component protein, Mov10.   
There is even more evidence that RNA granules inhibit HIV-1 replication in 
the producer cell by affecting translation of HIV-1 RNA.  HIV-1 has also been 
shown to actively suppress expression of a specific cellular miRNA cluster, 
thereby enhancing virus replication.  Other specific cellular miRNAs were also 
shown to prevent HIV-1 mRNA translation by targeting the 3’UTR of HIV-1 RNA 
to transport the miRNA-bound viral RNA into RNA granules containing the RNA-
induced silencing complex (RISC).  Disruption of RNA granules or RISC by 
siRNA-mediated knockdown (of Drosha, Dicer, DGCR8, RCK/p54, GW182, LSm-
1, or XRN1) relieved the restriction and enhanced HIV-1 p24 antigen levels in 
supernatants of cultures of infected cells that lack A3G.  Knockdown of RCK/p54 
shifted HIV-1 mRNA from the non-polysomal fraction to polysomes as compared 
to control siRNA transfected, A3G-negative cells.  Other data indicate that 
miRNAs may also cause transcriptional gene silencing through epigenetic 
effects.  In these earlier reports, the roles of RNA granules and miRNAs in HIV-1 
replication have largely been studied without analysis of a contribution of A3G, 
although one did note that A3G decreased HIV-1 p24 in culture supernatant 
fluids both with, and without, knockdown of P-body proteins.   
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I also recently identified that these A3G complexes were involved in a 
novel anti-HIV-1 restriction.  Cells containing A3G complexes produced 
significantly fewer virions than cells containing an A3G mutant (C97A A3G) that 
failed to form A3G complexes.  Differences in Vif-negative versus Vif-positive 
HIV-1 production were only seen in the presence of A3G, indicating that A3 
proteins degraded by Vif caused this inhibition. In the experiments described 
here, I aimed to verify, or refute, that A3G complexes, and not LMM A3G, were 
required for the decreased HIV-1 production I characterized as due to A3G.  
Also, NL4.3 ∆vif replication was reduced in HeLa-A3G cells when compared to 
replication in HeLa cells, which contain no A3G.  Recently, it was shown that P-
bodies can prevent HIV-1 mRNA translation via a microRNA, miR-29A, which 
targets the 3’UTR of HIV-1 (2, 102).  miRNA 29A transports viral RNA into P-
bodies and decreases HIV-1 translation.  Disruption of P-bodies by siRNA-
mediated knockdown of RCK/p54 not only abrogated P-body formation but 
relieved the restriction by the miRNA and enhanced HIV-1 translation (102).  
RCK/p54 and GW182 were each knocked down to assess effects on A3G 
complexes because of their reported differential distribution in RNA granule sub-
types. 
Knockdown of RCK/p54 successfully abrogated formation of RNA 
granules in cells containing and lacking A3G.  When cells containing A3G were 
infected after RCK/p54 knockdown, percent Vif-negative HIV-1 p24 antigen 
production was significantly increased compared to infected A3G complex-
containing cells treated with the control shRNA vector. In contrast, GW182 
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knockdown abrogated RNA granules in cells lacking A3G, but did not affect 
formation of A3G complexes. The inhibition of Vif-negative HIV-1 production was 
not altered by GW182 knockdown, relative to control shRNA treatment. This 
adds to evidence that A3 proteins in complexes, and not just diffusely localized 
A3 proteins, are required for the inhibition in producer cells.  Differences in the 
effects of GW182 versus RCK/p54 knockdown on HIV-1 production levels 
support the hypothesis that the mechanism of anti-HIV activity of A3G-containing 
RNA granules differs from that of RNA granules lacking A3G. 
 
Materials and Methods 
 
Cell culture, viral stocks, and infections 
HeLa and HeLa-A3G cells were maintained in DMEM supplemented with 
10% fetal bovine serum (FBS, HyClone), penicillin (50 IU/ml), and streptomycin 
(50 µg/ml). HIV-1 p24 antigen ELISA was carried out as previously described 
(156, 161).  Virus-containing supernatant fluids were collected and filtered 
through a 0.45 µm syringe filter.  The percentage p24 production was calculated 
as culture supernatant ultracentrifugation pellet p24 antigen concentration 
divided by the total p24 antigen concentration (cell + culture supernatant 
ultracentrifuge pellet concentration).  Cellular and viral lysates were prepared 
using ice cold lysis buffer [50mM HEPES, pH 7.4, 125mM NaCl, 0.2% NP-40 and 
0.1mM PMSF and EDTA-free protease inhibitor cocktail (CalBiochem, San 
Diego, CA #539137)].   
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RCK/p54 and GW182 shRNA-mediated knockdown 
 
Knockdown of RCK/p54 and GW182 was performed using 100 nM of an 
shRNA-expressing construct, as described by others (85) (Dharmacon).  HeLa or 
HeLa-A3G cells were seeded in a 6-well plate and grown overnight to 60% 
confluency. One day after plating, cells were transfected by Lipofectamine 2000 
(Invitrogen) with non-specific scrambled, GW182, or RCK/p54-specific shRNA. 
On day two, cells were trypsinized, spun down and washed in PBS 5 times, and 
then replated.  Four hours after trypsinization, cells were transfected a second 
time with either scrambled, GW182, or RCK/p54-specific siRNA.  In experiments 
using HeLa cells, cells were co-transfected with A3G-HA during the second 
transfection.  Cells were imaged by confocal microscopy performed after staining 
with anti-A3G antibody (polyclonal A3G antibody, NIH AIDS repository #9968) 24 
hours after the second transfection. HeLa-A3G cells were used for HIV-1 
infection experiments and an expression plasmid, CMX-44X (CD4), that 
expresses a tail-less CD4 that allows for high expression levels, was co-
transfected with the shRNA vector during the first transfection (93, 181). CD4 
protein levels were immunoblotting using rabbit anti-CD4 antibody (Sigma-
Aldrich).  Infection with HIV-1 virus stocks (either NL4.3 ∆vif or wild-type NL4.3) 
occurred on day 2 after trypsinization. Four hours after infection cells were 
washed 3 times to completely remove inocula, and virus production was 
assessed 24 hours after infection. 
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Immunofluoresence and Confocal Microscopy 
Cells for imaging were grown in 6 well plates on 22mm cover slips, and 
then fixed with 3.7% formaldehyde for 5 minutes at room temperature.  Cells 
were permeabilized with 0.1% Triton X-100 for 5 minutes.  Permeabilized cells 
were blocked in 5% BSA for 1 hour at room temperature.  Nuclei were stained 
with 1:1000 dilution of To-Pro 3 in PBS for 20 mins.  Primary antibodies were 
diluted in antibody dilution buffer (1% BSA, 0.05% NP-40, and 2% goat serum in 
PBS at a concentration of 1:500) (and incubated on cells for 1 hour.  Following 1 
hour incubation cells were washed 3 times with wash buffer (1% BSA and 0.05% 
NP-40) for 5 minutes.  Secondary antibodies anti-mouse Alexa Fluor 546, anti-
goat Alexa Fluor 568, and anti-rabbit Alexa Fluor 488 Invitrogen (Eugene, 
Oregon) were diluted in antibody dilution buffer at a concentration of 1:1000.  
Primary antibodies directed against PABP (sc-18611), GW182 (sc-47036), Dcp1 
(sc-100706), RCK/p54 (sc-51415), TIA-1 (sc-28237) and HA; all were obtained 
from Santa Cruz (Santa Cruz, CA).  Images were acquired using a Carl Zeiss 
LSM 510 Meta confocal microscope. All images shown are the middle section of 
a z-series, to better show colocalization and decrease background. 
Transfections for imaging were performed by transient transfection using 
polyethylenimine (PEI) (118).  Complete growth media was replaced 30 minutes 
prior to transfection.  The transfection reaction included 2ug of DNA and 10 µg of 
PEI diluted in 250 µl of serum-free media.   
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Biochemical fractionation of A3G 
A previously validated ultracentifugation method was used to characterize 
the form of A3G in cell cytoplasm.   HeLa-A3G-CD4 cells were infected.  
Confluent 100 mm plates of cells were rinsed with cold PBS, lysed with 500 µL 
cold lysis buffer, and vortexed for 10 minutes.  Cell lysates were clarified at 
17,900 x g for 10 minutes to remove nuclei.  The supernatant was removed and 
the pellet was resuspended in lysis buffer at a volume equal to that of the 
supernatant fluid.  Equal volumes of resuspended pellet and supernatant were 
then analyzed by western blot.  Proteins were resolved by 10% SDS-PAGE.  
Proteins were transferred to a nitrocellulose membrane and blocked overnight in 
5% milk. The membrane was probed with a polyclonal anti-A3G antibody (NIH 
AIDS repository #9968) and washed with PBST (0.05% Tween 20). 
 
Results 
 
A3G complexes co-localize with RNA granule markers 
 I studied if proteins associated with different RNA granule sub-types co-
localized with A3G complexes.  HeLa cells were transfected with A3G-HA.  24 
hours post-transfection cells were fixed and stained for immunofluoresence using 
anti-p54, anti-GW182, or anti-Dcp1 antibodies and anti-HA to visualize A3G-HA.  
Fig. 3-1 shows colocalization of A3G-HA with p54 (top row), GW182 (middle 
row), and Dcp1 (bottom row).  I found a high degree of co-localization with each 
marker.  The number and shape of the bodies differed from cell to cell, 
 74
reminiscent of P-bodies.  Panel B shows HeLa cells that stably express A3G.  
The staining pattern of this endogenous A3G is similar to that found in cells 
transfected with exogenous A3G-HA.  
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Figure 3-1. A3G complexes co-localize with RNA granule markers. A. Shown are confocal 
micrographs of HeLa cells transfected with A3G-HA. Cells have been stained with specific 
antibodies (see text) to visualize endogenous P-body marker proteins (125) and A3G (green), as 
well as incubated with To-Pro 3 to visualize the nucleus (blue). Areas of co-localization are seen 
as yellow in the last column (overlay). B.  Shown is a confocal micrograph of a HeLa-CD4-A3G 
cell.  Cells were stained with A3G-specific antibody to visualize endogenous A3G (green) and To-
Pro 3 to visualize the nucleus (blue). 
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shRNA knockdown of RCK/p54 abrogates Dcp1 and A3G co-localization 
 Structural components of RNA granules have been shown to be critical to 
their stability.  Knockdown of different protein components often abrogates 
granule formation.  I used shRNA’s directed against RCK/p54 to determine the 
effect on Dcp1 and RCK/p54 localization with and without A3G expression.  Fig. 
3-2A shows HeLa cells stained for the indicated markers.  Cells in the bottom 
panel of Fig. 3-2A were co-transfected by PEI with an A3G-HA plasmid; cells in 
upper and middle panels are untransfected and stained for endogenous proteins.  
In the left column are cells transfected with scrambled control shRNA and the 
right column shows cells transfected with the p54-specific shRNA construct.  The 
first row is stained for RCK/p54 and shows cells with and without p54 
knockdown.  No p54 is observed after knockdown.  In the middle panel, Dcp1 is 
also shown before and after knockdown and the localization changes 
significantly, from localization to granules to being exclusively diffuse.  The same 
is seen for A3G. Without p54 knockdown A3G is localized mainly to complexes.  
However, is observed exclusively as diffuse in the cytoplasm after p54 
knockdown.  These results suggest that RCK/p54 is a major structural 
component of granules containing both Dcp1 and A3G.   
 Fig. 3-2B shows western blots of cells HeLa after p54 knockdown.  The 
top gel shows p54 after treatment with scrambled control versus p54-specific 
shRNA.  The amount of p54 is significantly decreased by shRNA.  The amount of 
β-actin in the lower panel is similar before and after knockdown.  Fig. 3-2C is 
ultracentrifugation of cell lysates either transfected with scrambled control (left 2 
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lanes) or p54-specific shRNA (right 2 lanes).  A3G is found in all lanes except the 
pellet fraction of the p54-specific shRNA-treated cell lysate, consistent with my 
confocal data.  Fig. 3-2C shows cell lysates from cells used in Fig. 3A, bottom 
row.  These HeLa cells were transfected with A3G-HA and either scrambled 
shRNA in lanes 1 and 2, or p54-specific shRNA in lanes 3 and 4.  Lysates were 
then subjected to ultracentrifugation to separate the pellet and supernatant 
fractions.  The immunoblot shows A3G in each fraction and the absence of A3G 
in the pellet fraction when cells were transfected with the p54-specific shRNA, 
lane 4. 
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 Figure 3-2. shRNA knockdown of RCK/p54 abrogates Dcp1 and A3G co-localization. A. HeLa 
cells were transfected with either scrambled (left column) or p54-specific (right column) shRNAs 
on days 1 and 2 after cells were plated. Nuclei were stained using To-Pro 3 (blue) in each panel. 
B. Cells used in A, upper panel, were lysed on day 1 after second shRNA transfection and 
subjected to western blot analysis to show degree of p54 knockdown. Cells transfected with 
scrambled shRNA are in the first lane and cells transfected with p54-specific shRNA in the 
second. β-actin staining is depicted in the lower panel as a loading control. C. Lysates from cells 
used in A, lower panel were subjected to ultracentrifugation to separate A3G complexes (pellet, 
P) from A3G not in complexes (supernatant, S) fractions. Fractions were immunoblotted with an 
anti-HA antibody. Ultracentrifuge fractions from cells co-transfected on day 2 with scrambled 
shRNA and A3G-HA are in lanes 1 and 2 and those from cells co-transfected on day 2 with p54-
specific shRNA and A3G-HA are in lanes 3 and 4. 
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shRNA knockdown of GW182 abrogates Dcp1 but not A3G granule 
localization 
 
I next determined the effects of GW182 knockdown on Dcp1 granule 
localization and A3G complex formation.  Fig. 3-3A shows confocal images of 
HeLa cells that have been either transfected with a scrambled control shRNA 
(left column) or GW182-specific shRNA construct (right column).  GW182 is 
localized to granules in the control, but granules are not detectable following 
knockdown.  Dcp1 showed granule localization before knockdown, but following 
knockdown was only seen diffusely in the cytoplasm.  A3G-HA was shown to 
localize to complexes before and after GW182 knockdown.  This indicates that 
GW182 is not an essential component of all A3G-HA containing granules or that 
it is a component of only a small proportion of A3G complexes.  This is consistent 
with the literature that RNA granules are dynamic structures and their protein 
components differ depending on function. 
 Western blots of HeLa cells with and without GW182 knockdown are 
shown in Fig. 3-3B.  Fig. 3C shows HeLa cell lysates stained for A3G after 
ultracentrifugation from either cells transfected with scrambled (lanes 1 & 2) or 
GW182-specific  shRNA (lanes 3 & 4).  A3G is found in both the pellet and the 
supernatant with and without GW182 knockdown, indicating that GW182 has 
little to no effect on A3G complex localization. 
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 Figure 3-3. shRNA knockdown of GW182 abrogates Dcp1 but not A3G granule localization. A. 
HeLa cells were transfected with either scrambled (left column) or GW182-specific (right column) 
shRNAs on days 1 and 2 after plating. B. Cells used in A, upper panel, were lysed on day 1 after 
second shRNA transfection and subjected to western blot analysis to show degree of GW182 
knockdown. Cells transfected with scrambled shRNA are in the first lane and cells transfected 
with GW182-specific shRNA in the second. β-actin staining is depicted in the lower panel as a 
loading control. C. Lysates from cells used in A, lower panel were subjected to ultracentrifugation 
to separate A3G complexes (pellet, P) from A3G not in complexes (supernatant, S) fractions. 
Fractions were immunoblotted with an anti-HA antibody. Ultracentrifuge fractions from cells co-
transfected on day 2 with scrambled shRNA and A3G-HA are in lanes 1 and 2 and those from 
cells co-transfected on day 2 with GW182-specific shRNA and A3G-HA are in lanes 3 and 4. 
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A3G expression allows Dcp1 to retain its localization to granules in GW182 
knockdown cells 
 
Previously, I demonstrated that Dcp1 becomes diffuse and loses its 
localization in complexes following GW182 knockdown in the absence of A3G.  
However, transfected A3G remains localized to complexes following GW182 
knockdown.  Since A3G and Dcp1 co-localize under normal cellular conditions, I 
tested if Dcp1 would remain colocalized with A3G complexes after GW182 
knockdown in cells containing A3G.  HeLa cells were cotransfected with an A3G-
HA expression plasmid and a GW182-specific shRNA construct.  Cells were then 
stained to visualize A3G-HA, GW182, Dcp1, or RCK/p54.  Confocal micrographs 
in Fig. 3-4 show that when A3G was co-expressed in GW182 deficient cells, 
Dcp1 could be found localized with A3G complexes.  Therefore, A3G expression 
allows Dcp1 to retain its localization to A3G complexes, even in the absence of 
GW182.  
Panel A shows that GW182 was effectively knocked down in these cells, 
but A3G complexes were found.  Panel B shows that HeLa cells with GW182 
knocked down and A3G expression retain co-localization of Dcp-1 to A3G 
complexes, in contrast to the diffuse localization of Dcp-1 seen with GW182 
knockdown when  A3G-HA is not expressed (Fig. 3-3A).  Panel C shows that 
A3G-HA and p54 also colocalize in cells with GW182 knocked down. 
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 Figure 3-4. A3G expression allows Dcp1 to retain its localization to granules in GW182 
knockdown cells. P-body markers were imaged after co-transfection of A3G-HA and GW182-
specific shRNA.  A. shows antibody staining for endogenous GW182 on day 1 after two GW182-
specific shRNA transfections with co-transfection of A3G-HA along with the second GW182-
specific shRNA transfection. B. shows antibody staining for endogenous Dcp1 on day 1 after two 
GW182-specific shRNA transfections with co-transfection of A3G-HA along with the second 
GW182-specific shRNA transfection. C. shows antibody staining for endogenous p54 on day 1 
after two GW182-specific shRNA transfections with co-transfection of A3G-HA along with the 
second GW182-specific shRNA transfection. 
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Effect of RCK/p54 knockdown on HIV-1 replication  
 
I next tested whether loss of A3G complex formation by knockdown of 
RCK/p54 would reverse the decreased HIV-1 production associated with A3G 
complexes. I infected Hela-A3G cells (HeLa cells that constitutively express A3G) 
with HIV-1 NL4.3 ∆vif after transfection with CD4 and either scrambled or 
RCK/p54-specific shRNAs. HeLa-A3G cells infected with NL4.3 ∆vif after 
RCK/p54 knockdown produced about 50% more virus than was produced from 
control scrambled shRNA-treated HeLa-A3G cells infected with NL4.3 ∆vif  (Fig. 
3-5A, two bars on the left; Mann-Whitney U, P = 0.0004. There was no difference 
in Vif-positive, HIV-1 NL4.3 virus production from HeLa-A3G cells transfected 
with the control versus RCK/p54-specific shRNAs (Fig. 3-5A, two bars on the 
right). The non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) was 
used in all infections to limit infection to a single round.   
 Immunoblots of cell lysates showed that the HeLa-A3G cells infected with 
NL4.3 ∆vif and either transfected with scrambled (lane 1) or RCK/p54-specific 
(lane 2) shRNAs both contained A3G (Fig. 3-5A, upper panel below graph, lanes 
1 and 2). However, A3G was not detected in Vif-positive, HIV-1 NL4.3 virus-
infected cells transfected with either shRNA (Fig. 3-5A, upper panel below graph, 
lanes 3 and 4). RCK/p54 was decreased by the RCK/p54-specific, and not the 
scrambled, shRNA in cells infected with either virus (Fig. 3-5A, second panel 
below graph). Gag immunoreactivity was equivalent in each infection (Fig. 3-5A, 
third panel below graph). Anti-CD4 staining showed equivalent HIV-1 receptor 
protein levels in cells (Fig. 3-5A, fourth panel below graph). Anti-β-actin staining 
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indicated equivalent amounts of protein loading (Fig. 3-5A, bottom panel below 
graph). HIV-1 NL4.3 ∆vif-infected HeLa-A3G cells contained A3G in both pellet 
and supernatant ultracentrifuge fractions; the pellet fraction indicates the 
presence of A3G complexes (Fig. 3-5C, Lane 1, supernatant, and 2, pellet). No 
endogenous A3G was detected in either the ultracentrifuge pellet or supernatant 
fractions of HeLa-A3G cells infected by Vif-positive, wild type NL4.3 (Fig. 3-5C, 
lane 3, supernatant, and 4, pellet). In addition, transfection of RCK/p54-specific 
shRNA, and not scrambled shRNA, again led to diffuse staining of endogenous 
A3G throughout the cytoplasm in Hela-A3G cells and no evidence of A3G 
complexes on confocal microscopy (Fig. 3-5D).  
 Others have reported that A3G decreased absolute supernatant p24 
levels whether RCK/p54 or Lsm-1 were knocked down or not.  Similar results, 
and the finding that RCK/p54 knockdown increased supernatant p24 levels in the 
presence and absence of A3G, are noted here (Fig. 3-5B).  
 HeLa cells that contain no endogenous A3G were also transfected with 
CD4 and either of the two shRNAs prior to infection with NL4.3 or NL4.3 ∆vif to 
serve as an additional control. Production of Vif-positive and Vif-negative HIV-1 
did not differ with RCK/p54 knockdown that causes loss of P-bodies in these 
cells that lack A3G expression (data not shown). This corroborates the Vif-
positive HIV-1 infection of HeLa-A3G cells (Fig. 3-5A, right panel) as evidence 
that reversal of the decrease in HIV-1 NL4.3 ∆vif production by RCK/p54 
knockdown was specific for the loss of A3G complexes. 
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 Figure 3-5. Effect of RCK/p54 knockdown on HIV-1 replication. A. HeLa-A3G cells were 
transfected with CD4 and either scrambled or p54-specific shRNA’s. These transfected cells were 
then infected with wild-type NL4.3 or NL4.3 ∆vif. There was a significant difference in virus 
production between NL4.3 ∆vif infected cells transfected with scrambled and p54-specific 
shRNAs (Mann-Whitney, p < 0.0004). There was no significant difference among cells infected 
with wild-type NL4.3 that had different shRNAs. In the lower panel, cell lysates were analyzed by 
western blot. B. Supernatant p24 levels from the experiment in A.  C. Cell lysates from CD4-
expressing HeLa-A3G cells infected with either NL4.3 ∆vif or wild type NL4.3 were subjected to 
ultracentrifugation to separate the fraction containing A3G complexes (pellet, P) from the fraction 
containing non-complexed A3G (supernatant, S). Lanes 1 and 2 are cells infected with NL4.3 ∆vif 
and Lanes 3 and 4 are cells infected with wild type NL4.3 that contains an intact vif gene that is 
capable of degrading A3G. A3G was completely depleted from cells by Vif. A3G complexes were 
present in pellet in NL4.3 ∆vif infected cells. D. are images of HeLa-A3G cells transfected with 
either scrambled shRNA control (top row) or p54-specific shRNA (bottom row).  Cells were fixed 
and stained for endogenous A3G and RCK/p54. 
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Figure 3-6.  Effect of GW182 knockdown on HIV-1 replication. A. HeLa-A3G cells were 
transfected with CD4 and either scrambled or GW182-specific shRNA’s. These transfected cells 
were then infected with wild-type NL4.3 HIV that degrades A3G or NL4.3 ∆vif. There were no 
significant differences in virus production.  In the lower panel, cell lysates were analyzed by 
western blot. B. supernant p24 levels from the experiment in A.  C. shows images of HeLa-A3G 
cells transfected with either scrambled shRNA control (top row) or GW182-specific shRNA 
(bottom row).  Cells were fixed and stained for endogenous A3G and GW182. 
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Effect of GW182 knockdown on HIV-1 replication   
 I next tested whether knockdown of GW182 had an effect on HIV-1 
production in the presence and the absence of A3G. Hela-A3G cells (that stably 
express A3G) were infected with either NL4.3 or NL4.3 ∆vif following 
transfections with the CD4 receptor for HIV and either scrambled, or GW182-
specific, shRNAs (Fig. 3-6A). Transfection with GW182-specific shRNA had no 
effect on virus production when A3G was either present or depleted by Vif, 
although A3G depletion by Vif did increase virus production (Fig. 3-6A).   
 These results are consistent with p54 knockdown, and not GW182 
knockdown, abrogating both A3G complexes and their functional effect to 
decrease HIV-1 production. HeLa-CD4 cells that contain no endogenous A3G 
served as a control (data not shown). Beneath graphs in panel A are western 
blots are of cell lysates from experiment in the graph above it.  Westerns of 
GW182, Gag, CD4, and actin are shown.  Equivalent levels of Gag, CD4, and 
actin show cells were equally infected and control for protein loading on the gel.  
The first two lanes are cells infected with NL4.3 ∆vif and either transfected with 
scrambled or GW182-specific shRNAs.  A3G is present in equal amounts in all 
cases.  However, in lanes 3-4 A3G is degraded by Vif in cells infected with wild 
type NL4.3.  Transfection with shRNAs does not inhibit A3G degradation by Vif.   
In Fig. 3-6B, supernatant p24 levels are shown.  There was no significant 
difference in p24 levels when HeLa-A3G cells were infected with NL4.3 ∆vif.  
There is a significant difference in supernatant p24 levels when cells were 
infected with wild-type virus.  Fig. 3-6C, shows HeLa-A3G cells stained for A3G 
 88
and GW182.  In the top row are cells transfected with control scrambled shRNA.  
The bottom row are cells transfected with GW182-specific shRNA.  
 
RCK/p54 and GW182 knockdowns varying effects on HIV-1 release 
Other results supported the conclusion that knockdown of RNA granules 
containing A3G had different effects on HIV replication than did knockdown of 
granules not containing A3G. This is in addition to the results in Fig. 3-5 that A3G 
decreased absolute supernatant p24 levels whether RCK/p54 was knocked down 
or not and that RCK/p54 knockdown increased supernatant p24 levels in the 
presence and absence of A3G. The complete data from controls, as well as 
RCK/p54 and GW182 knockdowns are depicted in Table 3-1. Kruskal-Wallis 
analysis was significant for differences, and individual comparisons of mean p24 
values from each knockdown to controls were therefore tested by Mann-Whitney 
U tests.  Because there were 32 different comparisons, a Bonferroni correction 
for the level of significance was applied (0.05/32=0.015). Asterisks in the table 
indicate a significance level <0.015. 
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Table 3-1. RCK/p54 and GW182 knockdowns varying effects on HIV-1 release.  The table shows 
HIV p24 antigen levels from the experiments in Fig. 3-5 and 3-6.  The table details levels in the 
cell lysate, the ultracentrifuged supernatant, the total (sum of cell and supernatant), and the 
percent p24 production (supernatant / cell + supernatant). Percent p24 production does not 
change with Rck/p54 or GW182 knockdown in HeLa-A3G cells infected with Vif-positive virus 
(which degrades A3G) or in HeLa cells (lacking A3G) infected with either vif-negative or –positive 
virus. Asterisks indicate a significant difference, p < 0.015, when compared to the matched 
control. 
 
 
 90
Discussion 
Another group showed that knockdown of RCK/p54, Lsm1, or Ago2 in 
293T cells (not containing A3G) disrupted P-body formation and that subsequent 
transfection of an A3G expression vector led to A3G being seen only diffusely 
throughout the cytoplasm without localization to RNA granules (26).  I sought out 
to understand the nature of the relationship between A3G and RNA granules.  
Like others I see that A3G complexes colocalize with various markers for RNA 
granules (Fig 3-1).  Work is increasingly showing that RNA granules are highly 
dynamic structures (8, 73, 81, 147, 160, 176).  The complexity of their 
arrangement is immense.  These structures assemble the necessary proteins to 
mediate a certain function and can readily disassemble after that function is 
completed.  The dynamic nature of A3G complexes has yet to be studied in 
depth, but will likely line up with the new knowledge of RNA granules, that they 
are highly dynamic structures whose protein and RNA components can change 
rapidly depending on the state of the cell (176). 
 I chose two known P-body components RCK/p54 and GW182 to study the 
interaction of A3G complexes and RNA granules (47, 48, 72, 85, 131, 148, 171, 
172).  The knockdown of GW182 has been shown in several species to lead to 
abrogation of granules rich in GW182 (88, 120).  In cells in which I knocked down 
RCK/p54, Dcp1 and A3G granule localization was abrogated.  This is in line with 
work by Rana and colleagues that found RCK/p54 knockdown caused A3G to 
lose its localization to complexes (102).  My data demonstrated that RCK/p54 
was likely enriched in granules containing dcp1 and A3G.  This may give clues 
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as to the cellular function of A3G granules, as RCK/p54 is a DEAD box protein 
and as such acts as an RNA helicase (4, 95, 100).  Indeed, A3G complexes have 
been shown to sequester the RNA of Alu retrotransposons and RCK/p54 could 
function to initiate steps of RNA degradation (32, 63). 
 I next knocked down GW182 and found that like with p54 knockdown 
Dcp1 granule localization was abrogated.  However, A3G complexes were still 
observed (Fig 3-3A).  These results lead us to hypothesis that A3G complexes 
were low in GW182, while Dcp1 localizes to various granules some that are 
GW182 high and some GW182 low.  Recent discoveries have shown that indeed 
some RNA granules are rich in GW182 whereas others seem to be completely 
devoid of GW182 (23, 55, 153).  Clear evidence that “P-bodies” are not a single 
entity, but that groups of proteins come together in an orchestrated manner to 
perform a function, mostly related to mRNA metabolism.  GW182 and RCK/p54 
are critical for miRNA-mediated silencing of mRNA (34, 39, 46, 144).  These 
results could indicate that these granules colocalize with A3G complexes, but 
may be separate entities and that A3G may play little to no role in miRNA 
function. 
 Given my results on the difference in the response of Dcp1 and A3G to 
GW182 knockdown, I looked to determine if A3G expression during GW182 
knockdown would allow a portion of Dcp1 to remain in granules.  HeLa cells were 
co-transfected with A3G-HA and GW182-specific shRNAs and 24 hours post-
transfection stained for endogenous Dcp1 or A3G-HA.  Knockdown was 
confirmed by western blot.  Fig. 3-4 shows that with A3G-HA expression Dcp1 
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still retains some granule localization at A3G complexes.  This is unlike what I 
found in the absence of A3G in Fig. 3-3A.  These results indicate that Dcp1 is 
likely a component of the A3G complex.  Dcp1 role as a decapping enzyme 
suggests this process is important in the function of A3G complexes and may be 
a mechanism by which A3G complexes restrict Alu retrotransposition (21, 126, 
169).  
 Finally, I sought to extend finding I recently discovered that show that A3G 
complexes can restrict HIV-1 Gag release from infected cells.  Since p54 
knockdown abrogated A3G granule localization, I wanted to determine if these 
cells were relieved of the A3G-mediated restriction on HIV-1 release.  HeLa cells 
expressing both CD4 and A3G were infected with NL4.3 or NL4.3 ∆vif.  Cells 
were either transfected with a scrambled shRNA, p54-, or GW182-specific 
shRNA.  Results show that at 24 hours post-transfection cells transfected with 
the p54-secific shRNA were relieved of the A3G restriction on HIV-1 release.  
While cells transfected with scrambled or GW182 shRNAs were not.  I also 
determined if any of the knockdowns had an effect on HIV-1 release in the 
absence of A3G, using wild-type NL4.3, in which Vif was able to degrade 
endogenous A3G.  Whether the A3G-deleted cells were transfected with 
scrambled, p54-, or GW182-specific shRNAs there were no difference on the 
amount of virus released.  In all cases, these cells released amounts of virus 
similar to that released by cells with p54 knockdown and infected with Vif-
deficient NL4.3, suggesting that the lack of A3G, allowed normal levels of HIV-1 
release.  RCK/p54 knockdown does result in increased total p24 levels. This 
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effect of RCK/p54 knockdown is separate from the A3G-mediated restriction on 
HIV-1 production. 
 An independent consequence of RCK/p54 and GW182 knockdown is 
increased cellular and supernatant levels of p24, Table 3-1.  These increases are 
modest, but highly reproducible and are in line with published reports (26, 102).  
The mechanism that has been put forth by others is that micro RNAs normally 
target HIV-1 RNA for storage in P-bodies.  Upon abrogation of P-bodies, HIV-1 
RNA is released and translated at higher levels, resulting in increased virus 
production.  I agree with these earlier findings and show that this effect of P-body 
knockdown is independent of the A3G-mediated restriction, due to the fact that in 
all cases P-body knockdown resulted in higher cellular and supernatant p24 
levels, but percent p24 production was only decreased when A3G complexes 
were absent Fig. 3-5A. 
 RNA granules are highly dynamic structures and the study of their role in 
the HIV-1 lifecycle is of high importance (7, 147).  I show here that A3G may form 
a granule or complex along with RCK/p54 or GW182 that has distinct functions 
from a p54 or GW182-containing granule lacking A3G.  A3G complex formation 
is dependent on the presence of RCK/p54.  The fact that Dcp1 remains localized 
to granules in the absence of GW182 only when A3G is present indicates a 
separate structure.  This A3G complex is likely formed of many RNA binding 
proteins and RNAs.  It appears now that A3G complexes can restrict 
endogenous and exogenous retroviruses.  A3G complexes seem to be 
multifunctional structures whose presence inhibits the replication of HIV-1. 
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CHAPTER IV 
 
Conclusions and Future Directions 
 
Conclusions 
 This work has focused on the High Molecular Mass complex (HMM) form 
of A3G, a cytidine deaminase found within cells.  This large ribonucleoprotein 
complex, called the A3G complex here, was not known to play a role in any anti-
viral response prior to this work.  Previously, it had been shown that the A3G 
complex is enzymatically inactive for cytidine deaminase activity.  The major 
cellular role for the A3G complex was shown to be in restricting exogenous 
retroviruses, namely retroelements.  This work for the first time extends the role 
of the A3G complex to include an anti-HIV response. 
 I showed that A3G complexes are responsible for limiting the production of 
HIV in infected cells at a late step in replication.  I demonstrated that HIV Gag, 
the major polyprotein that drives HIV assembly colocalizes with the A3G 
complex.  Nearly, 30% of HIV Gag can be found at A3G complexes at a given 
time point.  The restriction of A3G complexes on virus production can lead to up 
to a 70% reduction in virion production following a single-round of infection.  This 
reduction was highly significant and highly reproducible.  This work was aided by 
the observation that a mutant of A3G, C97A fails to form complexes by 24 hours.  
I hypothesize that producer cell A3G complexes trap HIV Gag, thereby making it 
unavailable for assembly at the plasma membrane.  I found that HIV Gag in cells 
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containing A3G complexes had a shorter half-life than Gag in cells lacking A3G 
complexes.  This suggested that A3G complexes lead to increased HIV Gag 
turnover. 
 I also showed that A3G complexes are not necessary for the packaging of 
A3G within virions.  The other mechanism for A3G viral restriction is carried out 
in the target cell and thus it is essential for A3G to be packaged into progeny 
virions.  Using the C97A mutant of A3G, I demonstrated that the LMM form of 
A3G is packaged at levels near that of WT A3G.  This extended previous findings 
by others that newly synthesized A3G is packaged within the virus.  
 Finally, using RNAi I showed that RCK/p54 knockdown, but not GW182 
knockdown abrogates A3G complexes.  Both p54 and GW182 are markers for 
RNA granules; my results suggested that they represent two different cellular 
structures.  A3G may form a unique RNA granule that is only present when A3G 
is expressed in cells.  These A3G complexes contain both Dcp1 and p54.  A3G 
complexes likely contain little to no GW182.  These results indicate A3G 
complexes may form a unique RNA granule structure.  In cells with A3G 
complexes, a portion of Gag gets trapped within A3G complexes.  This leaves a 
smaller amount of Gag available for virus production.  Gag trapped in A3G 
complexes is likely targeted for degradation via an unknown mechanism. I 
hypothesized that this mechanism for A3G complex effects on HIV-1 replication 
in the producer cell differs from effects of RNA granules lacking A3G on HIV-1 
replication. In the latter case, the model predicts a different effect on HIV-1 
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replication, such as blocking translation of, or degrading, some Gag mRNAs  A 
schematic of this model is presented in Fig. 4-1. 
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Figure 4-1.  Predicted model of A3G-mediated restriction of HIV-1 production. The above 
schematic shows a typical cell with nucleus and endoplasmic reticulum in the middle.  Above the 
center line is the typical late stages of HIV-1 assembly.  Gag is made on ribosomes bound to the 
endoplasmic reticulum and then transits to the plasma membrane for budding and release.  
Where large numbers of viruses are produced in the absence of A3G complexes.  Below the line 
is what I predict occurs in cells with A3G complexes.  Gag is still made on bound ribosomes, 
however, a portion of Gag gets trapped within A3G complexes.  This leaves a smaller amount of 
Gag available for virus production.  Gag trapped in A3G complexes is likely targeted for 
degradation via an unknown mechanism that may involve late endosomes. 
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Significance 
In summary, I have shown that APOBEC3G has the ability to limit the 
production of HIV-1 in producer cells at a late (post-integration) step of viral 
replication if A3G is not degraded by Vif, that this antiviral effect is due to 
cytoplasmic complexes of A3G, and that these complexes are not identical to P-
bodies. A3G complexes may be as dynamic as other RNA granules now appear 
to be. The mechanism of their effect on late steps of HIV-1 replication is different 
and distinct from the effect of RNA granules that are abolished by GW182 
knockdown (now called GW-bodies), and also different and distinct from the 
effect of RNA granules abolished by RCK/p54 knockdown (likely P-bodies).  The 
different mechanisms of anti-HIV effect of these different RNA granules were 
apparent in the presence of absence of A3G. Some data that requires extension 
suggests that A3G complexes may sequester/degrade HIV-1 p24 protein, and 
that GW-bodies and P-bodies may decrease the translation or stability of HIV-1 
mRNA. Thus, I suggest that the effect of GW- and P-bodies cannot be reversed, 
unless A3G complex effects are also reversed.  
These results have significant implications for understanding the biology of 
RNA granules that are critical components of cells, as well as of HIV-1 
replication. This is the most important and basic aspect of my work’s significance, 
as increasing fundamental understanding of these important biological processes 
may have broad implications. There is also the potential for this work to lead to 
novel therapeutics for HIV-infected patients.  Manipulation of A3G complex 
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formation for therapeutic purposes by a small molecule would potentially allow for 
the production of fewer viruses and/or less infectious viruses. 
Disrupting the interaction of A3G and Vif could potentially lead to a new 
class of anti-retrovirals.  HIV-1 would theoretically have very limited chances to 
evade drugs that target the human A3G, rather than a viral protein, through 
development of drug resistant mutations.  Understanding the A3G complex may 
play a vital role in future development of therapies based on my findings. I show 
that Vif can degrade A3G both in the LMM form and in A3G complexes.  The 
interactions of A3G with Vif may change depending on if A3G exists as a 
monomer in the cytoplasm than when A3G is complexed with RNAs and proteins 
in complexes.  Protecting both A3G in the cytoplasm and within complexes would 
be an important consideration for future development of a Vif-A3G inhibitor, as 
now it is clear that the A3G complexes are not inactive against HIV-1 as 
previously thought. 
APOBEC3 proteins evolved long ago and have undergone little change.  
This indicates they play a major role in human survival.  The discovery that A3G 
has the ability to bind and sequester Gag away from the site of viral assembly 
could be extended to other viruses.  A3G is known to restrict several other 
viruses, and it is conceivable that A3G is able to sequester other viral molecules 
as well.  And even if A3G is not packaged into virions, maybe this producer cell 
effect of limiting virus production may contribute to reducing viral spread 
throughout the body. 
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The amount of A3G within patient lymphocytes may not be the only factor 
that influences disease progression.  My results suggest that the ratio of 
LMM:HMM A3G also may play a critical role.  It would be expected that patients 
with higher levels of HMM A3G may produce less virus.  On the other hand, 
patients with higher amounts of LMM A3G, will likely package more A3G into 
progeny virions to block replication in the target cell. Thus, this work suggests 
seeking an optimum ration that will maximize restriction of HIV-1 replication in the 
producer and the target cell.  The ratio of A3G complexes to the LMM form may 
also be studied further to determine utility to predict disease outcome, viral or 
immunological markers of disease progression, or effectiveness of HAART. 
 
Future Directions 
 This works sheds light on the role of A3G complexes during HIV-1 
infection.  I showed that the complex is not involved in the packaging of A3G into 
virions.  I then extended those findings to show that the A3G complex is involved 
in an anti-viral response that restricts the amount of HIV-1 produced from cells.  
There are many possible next steps.  I will outline some important experiments 
that I prioritize to further extend these results to lead to the potential significance 
described above. 
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Characterize the nature of the interaction between A3G complexes and HIV-1 
Gag   
I have shown by confocal microscopy that a significant portion of HIV-1 
Gag colocalizes with A3G complexes.  I show some evidence that this interaction 
leads to the restriction of HIV-1 release, and also that A3G complexes are not 
identical to other RNA granules.  However, the characterization of this 
interaction, and the complexity of RNA granules, can be greatly enhanced by the 
use of live cell imaging. 
 Live cell imaging would allow us a glimpse at the dynamic nature of A3G 
complexes.  To date, no study has examined the half-life of A3G complexes and 
this knowledge would help us to understand the role of A3G complexes in cells.  
It has been shown that A3G complexes can form within 30 minutes of A3G 
synthesis, but it is unclear how dynamic they are.  Live cell imaging would give 
us clues as to proteins transiting through A3G complexes.  These experiments 
would allow a next step to see if Gag is eventually released, or more likely 
degraded by the lysosome or proteasome.  I, and others have shown that A3G 
complexes can be found in close proximity to late endosomes and this may 
indicate that some of the constituents of A3G complexes may be turned over by 
the endosomal pathway.  Of note, GW-bodies also are now thought to play a role 
in directing miRISC components to these degradative compartments. A3G 
complexes may share similar protein markers with other RNA granules, but may 
in fact be distinct structures.  RNA granules are known for their ability to store or 
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degrade RNA’s, but maybe A3G complexes also lead to the degradation of 
specific proteins.  
 
Infectivity of wild-type NL4.3 and NL4.3 ∆vif viruses produced from cells with or 
without A3G complexes 
I have shown experiments that highlight the effect of A3G complexes on 
virus production.  However, we don’t know if virions produced in the presence or 
absence of A3G complexes have the same or different infectivities.  A3G 
complexes may affect the ability of other positive or negative factors on virus 
replication to be packaged into virions.  Further, the varying amount of A3G 
packaged could play a major role in virion infectivity. 
This experiment would allow us to understand any difference in infectivity 
of viruses produced in the absence or presence of A3G complexes.  I could 
utilize two approaches to studying the impact of no A3G complexes on viral 
infectivity.  I could compare cells transfected with wild-type A3G to cells 
transfected with the C97A mutant.  This would allow us to compare cells all with 
A3G, but only one condition having A3G complexes.  Further, I could use 
knockdown of RCK/p54 to abrogate A3G complexes and compare to cells 
transfected with a control-scrambled shRNA.  I know that A3G packaging does 
not require A3G complexes.  However, detailed analysis on the amount of A3G 
packaged in cells with or without A3G complexes has not been performed.  The 
virion content of A3G and virion infectivity would be determined. 
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There potentially could be great differences in the amount of A3G 
packaged when only LMM is present in the cell.  Since evidence points to LMM 
being the source of A3G within virions, increasing LMM in the cell would lead to 
much higher levels of A3G packaging.  This would likely lead to the production of 
virions with greatly reduced infectivity. There is potential for this strategy to 
contribute to a “functional cure” if ongoing replenishment of the reservoir occurs 
from virus replication during therapy. 
  
Enzymatically inactive C97A and WT A3G  
 All experiments I have presented have used A3G proteins that are 
enzymatically active.  Therefore, we do not know if enzymatic activity of A3G 
plays a role in the restriction on virus production by A3G complexes. 
In these experiments I would make use of mutants of A3G; the E259A 
mutant, that is known not to posses enzymatic activity.  The exact contribution of 
enzymatic activity to the target cell effect of A3G is still unclear.  Enzymatic 
activity likely plays a smaller role in A3G restricting the early stages of the viral 
lifecycle in the target cell than originally believed, but I have not addressed the 
need for enzymatic activity in the producer cell effect of A3G. 
 To extend my findings that A3G complexes are restricting HIV-1 release, it 
is necessary to understand the mechanism of this restriction.  I hypothesis that 
Gag localized within these complexes is not available for assembly at the plasma 
membrane and rapidly degraded.  If this is the case, I need to determine the fate 
of Gag that is sequestered in these complexes.  It is unlikely that this restriction 
 104
requires enzymatic activity, since the HMM complex of A3G is enzymatically 
inactive, but to rule out the role of cytidine deamination by A3G in restricting the 
release of HIV-1 Gag, this experiment is highly important. 
 
The role of protein degradation in A3G complex HIV-1 restriction 
 The role that protein degradation plays in the A3G-mediated restriction of 
HIV-1 release has only been minimally investigated.  I have found that A3G 
complexes colocalize with late endosomes about 24 hours after formation.  This 
colocalization may give us clues as to a role that A3G complexes play in protein 
turnover.   
 I also did an experiment in which translation in cells was blocked using 
cycloheximide.  I then followed the fate of HIV Gag in cells transfected with no 
A3G, wild-type A3G, or C97A A3G.  I found that HIV Gag in treated cells 
transfected with wild-type A3G was degraded much more rapidly than in cells 
with no A3G or C97A mutant that is severely delayed in A3G complex formation.   
 A3G complexes contain many proteins associated with processing bodies.  
A subset of these bodies, GW-Bodies are known to colocalize with late 
endosomes and multivesicular bodies or MVBs and play a role in turnover of the 
RISC complex associated with siRNA and miRNA.  Processing bodies have not 
been found to overlap with late endosomes and are thought of as distinct 
structures.  The fact that A3G complexes colocalize strongly with late 
endosomes, raises the possibility that they may be involved in protein turnover.   
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Additional experiments can be done where cells are co-transfected with 
WT A3G or C97A and HIV-1 Gag.  The amount of Gag found within lysosomes 
and exosome structures can be assessed by first subcellular fractionation and 
western blotting.  If the amount of HIV-1 Gag is higher in cells with A3G 
complexes it would suggest lysosomal degradation plays a role in A3G-mediated 
restriction of HIV-1 release.  Additionally, these experiments can be done in the 
presence or absence of lysosomal function, to determine if blocking the 
lysosomal degradation pathway leads to increased HIV-1 release in cells with 
A3G complexes, further implicating lysosomal degradation of HIV Gag as the 
reason for decreased HIV production in cells with A3G complexes. 
 
Spreading Infections of WT NL4.3 and NL4.3 ∆vif in CEM and CEM-SS cells 
 I have shown that A3G complexes greatly restrict the release of HIV-1 
from cells in a single-round of infection.  However, it will become important to 
understand the level of this restriction over the course of a spreading infection.   
These experiments would more reflect a natural infection. 
 In order to perform the following experiment, I would first have to separate 
the producer cell restriction on HIV-1 described here from the target cell effect of 
A3G.  This likely can be accomplished using mutants.  The discovery of an A3G 
mutant that lacks either the target cell or producer cell effect would greatly 
advance the field and aid in further studies of the long-term effects of these 
restrictions.   
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 Another means by which the target cell and producer cell effect could be 
separated is by using CEM and CEM-SS cells that contain no RCK/p54.  These 
cells would not allow A3G to form A3G complexes.  I could compare virus spread 
in sister cells with and without RCK/p54 expression to determine the effect of 
knocking out the producer cell effect.  An important control would be to make 
sure that RCK/p54 knockdown has no influence on the target cell effect of A3G. 
Once, a system is established that separates the target cell and producer 
cell restrictions of A3G, the following experiment could be performed.  In these 
spreading infection experiments both CEM and CEM-SS cells would be infected 
with either Vif-positive or Vif-negative HIV.  I have previously shown that HIV-1 
Vif is able to rid cells of both LMM and HMM A3G.  I have also shown that LMM 
A3G does not restrict HIV-1 production.  So, depleting cells of both LMM and 
HMM A3G should be an accurate reflection of the contribution of A3G complexes 
to HIV-1 production.  Virus would be collected over the course of weeks and the 
difference in NL4.3 and NL4.3∆vif should be observed in CEM cells, which 
posses A3G and CEM cells with RCK/p54 knocked down.  CEM-SS cells would 
be used as a negative control, since they do not contain A3G. 
 This experiment would more closely reflect what happens within patients.  
This experiment is complicated by the fact that virus output would be a result of 
the combined effects of the producer cell and target cell restrictions of A3G.  
However, during the experiment the amount of Gag and A3G association could 
be monitored by ultracentrifugation followed by western blots to visualize A3G 
and Gag.   
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 Determine how A3G complex formation is regulated 
 I know that A3G complexes contain many proteins and RNA’s.  However, 
there are likely still roles that A3G complexes play that are unknown.  An 
important step toward understanding the role of A3G complexes understands 
what signals govern their formation. 
 It does seem that T cell activation plays a role in A3G complex formation.  
Resting T cells posses higher levels of LMM compared to HMM A3G.  However, 
upon T cell activation, a majority of LMM A3G is converted to A3G complexes.  
Using resting and activated T cells as a model may be a way to tease apart the 
steps necessary for A3G complex formation.  Mutant cell lines that don’t readily 
shift their A3G into complexes after T cell activation would be useful in identify 
the factors necessary.  Also, cytokines may play a role and taking a closer look at 
those pathways, may yield important clues.  It is known that extracellular signals 
can influence the formation of HMM A3G, without cell activation.  Understanding 
how A3G complexes are formed will lead to a better understanding of their 
cellular functions. 
 
In conclusion, this work demonstrates that A3G complexes play an 
important role in an anti-HIV response in the producer cell.  This anti-viral role of 
A3G complexes was previously unknown, but likely plays an important role in 
vivo.  Making use of a mutant of A3G that was delayed in A3G complex formation 
was the initial finding that led to further investigation.  I first demonstrated that the 
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presence of A3G complexes was not necessary for A3G packaging into virions.  
Also, this mutant, C97A, allowed us to demonstrate that A3G complexes were 
linked to decreased levels of virus output.  Depletion of A3G complexes by HIV-1 
Vif and knockdown of p54 relieves this A3G-mediated restriction.  This work 
identified a new antiviral function of the cytidine deaminase A3G.  Further work 
on A3G complexes, will yield important clues as to any additional functions of 
A3G complexes and may lead to the development of therapies that will decrease 
the amount of virus output in patients.   
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